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ABSTRACT 
Blood substitutes have been sought for several centuries and in many 
ways. Hemoglobin-based blood substitutes are the most interesting among those 
because of hemoglobin's unique structure and function to transport oxygen. The 
tetrameric hemoglobin in solution can dissociate into dimers which are readily 
removed by the kidney. To overcome the limitations to hemoglobin, it can be 
modified by biotechnology and/or chemistry. In chemistry, molecular modification 
requires crosslinking of hemoglobin to prevent formation of dimers. One of the 
most interesting small regions of the hemoglobin molecule is the p cleft of the 
BPG binding site. A series of different kinds of crosslinking reagents were 
synthesized and reacted only with Val1, Lys82 and Lys144 of the ,8-chain of 
hemoglobin. The negative charge from the phosphate or carboxyl groups of the 
reagents has an electrostatic interaction with positive charges from the residues 
in the BPG cleft. 
For development of blood substitutes, a series of novel multi-(3,5-
dibromosalicyl) linkers were designed and synthesized for modification of 
hemoglobin in this dissertation. In addition to electrostatic effects, selectivity 
xviii 
and efficiency can be enhanced by taking advantage of steric effects which play 
an important role in determining the regioselectivity of organic reagents. 
Computer modeling techniques were utilized to model 3-dimensional structures 
of hemoglobin A molecules and deoxyhemoglobin crystal unit cells, and design 
crosslinkers. In a manner similar to that used in a successful synthesis and 
purification of tert-butyl salicylate, tert-butyl 3,5-dibromosalicylate was prepared 
using DCC to couple tert-butyl alcohol and 3,5-dibromosalicylic acid. The 
crosslinking reagents successfully synthesized include: Two bis-, two tris- and 
two tetrakis(3,5-dibromosalicyl) reagents, and one tetrakis(sodium methyl 
phosphate) reagent. 
Both oxy and deoxy hemoglobin were crosslinked with DBSTC. The 
denaturation transition (Tm) of the oxy crosslinked hemoglobin increased 14.5 °C 
and that of the deoxy crosslinked hemoglobin, 13.0 °C. The apparent rate 
constant (kapp) of autoxidation for the oxy crosslinked hemoglobin remained the 
same as native hemoglobin but that of the deoxy crosslinked hemoglobin 
increased by 34%. The higher oxygen affinity and lower cooperativity of the 
crosslinked proteins compared with native hemoglobin indicated that the 
crosslink shifted the conformation to the R state. 
The major species from reaction of deoxyhemoglobin with DBCPA 
contained high yields of both bi- and tri-linked proteins. The denaturation 
transition (Tm) of both bi- and tri-linked hemoglobins increased 14.0 °C. The 
apparent rate constant (kapp) of autoxidation for the crosslinked hemoglobins 
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remained the same as native hemoglobin. The bi-linked species had a lower 
oxygen affinity and unchanged cooperativity compared with native hemoglobin, 
while the tri-linked proteins exhibited increased oxygen affinity and decreased 
cooperativity. SOS-PAGE analysis showed multi-bands in dimer range, 
indicating heterogeneous reaction of DBCPA with hemoglobin because of the 
asymmetrical structure of the reagent. 
The elongated bi-linkers were designed to crosslink between Lys82P of 
two different hemoglobin tetramers. However, no octamers were isolated by gel 
filtration. The tetra-linkers were designed to crosslink between two hemoglobin 
tetramers with bi-linking of each hemoglobin between Lys82ps in one step. 
Besides dimeric bands, trimeric and tetrameric bands were shown by SDS-
PAGE, corresponding to tri-linking and tetra-linking of hemoglobin with the tetra-
linkers. 
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Chapter 1 
INTRODUCTION 
The lack of donor blood and possible 
complications with transfusion blood have been 
accentuated recently because of problems 
related to AIDS. As a result, there is an 
increasing interest in developing blood 
substitutes for transfusions and other 
applications. Two major areas of blood 
substitutes have been developed: (1) the 
biotechnological approaches, using modified 
hemoglobin, synthetic heme, and other 
approaches, and (2) the chemical approaches, 
using perfluorochemicals. The emulsion of 
perfluorochemicals can dissolve oxygen up to 
F-1,3-dimethyladamantane 70% per unit volume [1-2]. Perfluorochemicals 
are not antigenic and their sizes are so small 
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comparing with that of RBC's that they could pass through occluded blood 
vessels. Unfortunately, perfluorochemicals accumulate in the liver and in the 
spleen to the point that these organs are unable to clear other foreign 
substitutes when they are transfused to patients [3]. Hemoglobin, because of its 
unique structure and function to transport oxygen, becomes the most 
interesting potential blood substitute [4-6]. 
Structure of Hemoglobin 
Hemoglobin, the oxygen carrier of the blood, was the second protein 
whose structure was determined by X-ray crystallography [7, 8]. Myoglobin, the 
oxygen-storage protein of muscle was the first. Hemoglobin was also among 
CH2=CH 
Heme (Fe-protoporphyrin IX) 
the first to have its amino acid sequence determined. The protein is easily 
obtained in large quantities. Every milliliter of blood has approximately 5 billion 
erythrocytes or red cells, and each erythrocyte is packed with 280 million 
molecules of hemoglobin. 
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The capacity of hemoglobin to bind oxygen depends on the presence of a 
non-polypeptide unit, namely, a heme group. The heme also gives hemoglobin 
its distinctive red color. The heme consists of an organic part, protoporphyrin, 
and an iron atom. The iron atom in heme binds to the four nitrogens in the 
center of the protoporphyrin ring. The iron can form two additional bonds, one 
on either side of the heme plane. The iron atom can be in the ferrous ( +2) or the 
ferric (+3) oxidation state, and the corresponding forms of hemoglobin are 
called ferrohemoglobin and ferrihemoglobin (also called methemoglobin). Only 
ferrohemoglobin, the +2 oxidation state, can bind oxygen. 
Vertebrate hemoglobins consist of four polypeptide chains, two of one 
kind and two of another. The four chains are held together by noncovalent 
attractions. Each contains a heme group and a single oxygen-binding site. 
Hemoglobin A (Figure 1 ), the principal hemoglobin in adults, consists of two a 
chains with 141 amino acids and 15, 126 molecular weight each, and two p 
chains with 146 residues and 15,867 molecular weight each. The heme adds 
another 616 daltons to each chain, so the total molecular weight of the adult 
hemoglobin tetramer is 64,450 daltons. The three-dimensional structures of 
myoglobin and the a and p chains of human hemoglobin are strikingly similar. 
About 75% of the main chain is in an a-helical conformation. The eight major 
helical segment, all right-handed, are referred to as A, B, C, ... , H. The first 
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Figure 1. Hemoglobin A in the deoxy form. 
5 
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residue in helix A is designated A 1, the second A2., and so forth. Adults also 
have a minor hemoglobin (-2% of the total hemoglobin) called hemoglobin A2, 
which contains 8 chains in place of the f3 chains of hemoglobin A. Thus, the 
subunit composition of hemoglobin A is az/Ji., and that of hemoglobin A2 is az8i.. 
The hemoglobin molecule is nearly spherical, with a diameter of 55 A. The four 
chains are packed together in a tetrahedron. Each a chain is in contact with 
both f3 chains. In contrast, there are few interactions between the two a chains 
or between the two f3 chains. 
The heme groups are located in crevices near the exterior of the 
molecule, one in each subunit. The four oxygen-binding sites are far apart; the 
distance between the two closest iron atoms is 25 A. The highly polar 
propionate side chains of the heme are on the surface of a chain of hemoglobin. 
At physiological pH, these carboxylic acid groups are ionized. The rest of the 
heme is inside the chain of the hemoglobin, where it is surrounded by nonpolar 
residues except for two histidines. The iron atom of the heme is directly bonded 
to one of these histidines, namely, residue F8. This histidine, which occupies 
the fifth coordination position, is called the proximal histidine. The oxygen-
binding site is on the other side of the heme plane, at the sixth coordination 
position. A second histidine residue (E7), termed the distal histidine, is near 
the heme but not bonded to it. In aqueous solution, oxygen very rapidly 
oxidizes a ferrous heme to ferric heme which can not bind oxygen. In 
hemoglobin, the heme groups are much less susceptible to oxidation because 
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two subunits or two hemoglobin molecules cannot readily associate to form a 
heme-Orheme complex. The heme is protected in a hydrophobic binding 
pocket. 
The conformations of the three physiologically pertinent forms of 
hemoglobin - deoxy-, oxy- and ferri-forms (methemoglobin) - are very similar 
except at the sixth coordination position. In deoxyhemoglobin, it is empty; in 
oxyhemoglobin, it is occupied by 02; in methemoglobin, it is occupied by water. 
The axis of the bound 02 is at an angle to the iron-oxygen bond. The quaternary 
structure of deoxyhemoglobin is termed the T (tense or taut) form; that of 
oxyhemoglobin, the R (relaxed) form. In deoxyhemoglobin, the iron atom is 
Histidine FB 
\-NH 
Z .. > N 
I Heme plane 
Oxygenation 
\-NH 
Z .. > N 
_1 
I 
o~ 
0 
about 0.4 A out of the porphyrin plane toward the proximal histidine, so that the 
heme group is domed (convex) in the same direction. On oxygenation, the iron 
atom moves into the plane of the porphyrin to form a strong bond with 02, and 
the heme becomes more planar. The iron atom pulls the proximal histidine with 
it when it moves into the plane of the porphyrin. This movement of histidine FB 
shifts the F helix, the EF corner, and the FG corner. These conformational 
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changes are in turn transmitted to the subunit interfaces where they rupture 
interchain salt links to switch the protein to the R form. Thus, a structural 
change (oxygenation) within a subunit is translated into structural changes at the 
interfaces between subunits. The binding of oxygen at one heme site is thereby 
communicated to parts of the molecule that are far away. 
Oxygen-Binding of Hemoglobin 
0 H H 
Hemoglobin is an allosteric protein. 
II I I //0 
o--P-0-C-C-C The binding of 0 2 to hemoglobin enhances 
I I I 'o-o- H 0 
I 
o--P=O 
the binding of additional 02 to the same 
I o- hemoglobin molecule [7, 8). In other words, 
2,3-Bisphosphoglycerate (BPG) 0 2 binds cooperatively to hemoglobin. The 
affinity of hemoglobin for oxygen depends on pH. The C02 molecule also affects 
the oxygen-binding characteristics of 
hemoglobin. 
promote the release of bound 02. 
Reciprocally, 0 2 promotes the release 
of bound H+ and C02. The oxygen 
affinity of hemoglobin is further 
regulated by organic phosphates such 
as 2,3-bisphosphoglycerate (BPG) 
resulting in a low affinity for oxygen. 
E 
c: 
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Oxygen dissociation curve of Hb 
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A plot of Y, the saturation, defined as the fractional occupancy of all the 
oxygen-binding sites in a solution, versus p02, the partial pressure of oxygen, 
is called an oxygen dissociation curve. Oxygen affinity can be characterized by 
a quantity P50, which is the partial pressure of oxygen at which 50% of sites are 
filled (i.e., at which Y = 0.5). The oxygen dissociation curve of hemoglobin is 
sigmoidal, which agrees with the equation derived for the hypothetical 
equilibrium 
This expression yields 
(P02t 
Y=-----
(P02t + (Psot 
which can be rearranged to give 
Y p02 n 
-=(-) 
1 - Y Pso 
This equation states that the ratio of oxyheme (Y) to deoxyheme (1 - Y) is equal 
to the nth power of the ratio of p02 to P50. Taking the logarithms of both sides of 
the equation gives 
y 
log = n log p02 - n log Pso 
1 - y 
A plot of log [Y/(1 - Y)) versus log p02, called a Hill plot, approximates a 
straight line. Its slope n at the midpoint of the binding (Y = 0.5) is called the Hill 
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coefficient. The value of n increases with the degree of cooperativity; the 
maximum possible value of n is equal to the number of binding sites. 
The Hill coefficient of 2.8 for hemoglobin indicates that the binding of 
oxygen in hemoglobin is cooperative. Binding at one heme facilitates the 
binding of oxygen at the other hemes on the same tetramer. Conversely, the 
unloading of oxygen at one heme facilitates the unloading of oxygen at the 
others. In other words, the heme groups of a hemoglobin molecule 
communicate with each other. The cooperative binding of oxygen by 
hemoglobin enables it to deliver 1.83 times as much oxygen under typical 
physiological conditions as it would if the sites were independent. 
The oxygen affinity of hemoglobin within red cells is lower than that of 
hemoglobin in free solution. BPG binds to hemoglobin and has a large effect on 
its affinity for oxygen. This highly anionic organic phosphate is present in 
human red cells at about the same molar concentration as hemoglobin. In the 
absence of BPG, the P50 of hemoglobin is 13-16 mmHg. In its presence, P50 
became 26 mmHg. Thus, BPG lowers the oxygen affinity of hemoglobin by a 
factor of 2, which is essential in enabling hemoglobin to unload oxygen in tissue 
capillaries. BPG diminishes the oxygen affinity of hemoglobin by binding to 
deoxyhemoglobin but not to the oxygenated form. The binding site for BPG 
consists of multiple positively charged residues on each p chain: the a-amino 
group, His2, Lys82, and His143. These groups interact with the strongly 
negatively charged BPG which carries nearly four negative charges at 
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physiologic pH. On oxygenation, BPG is extruded because the central cavity 
becomes too small. Specifically, the gap between the H helices of the p chains 
becomes narrowed. Also, the distance between the a-amino groups increases 
from 16 to 20 A, which prevents them from simultaneously binding the 
phosphates of a BPG molecule. The reason why BPG decreases oxygen affinity 
is now evident. BPG stabilizes the deoxyhemoglobin quaternary structure by 
non-covalently cross-linking the p chains. In other words, BPG shifts the 
equilibrium toward the T form. The carboxyl-terminal residues of 
deoxyhemoglobin form eight salt links that must be broken for oxygenation to 
occur. The binding of BPG contributes additional salt links that must be broken, 
and so the oxygen affinity of hemoglobin is diminished. 
Denaturation of Hemoglobin 
A hemoglobin molecule retains its biological activity only when it is in the 
native state. One of the requirements for a suitable blood substitute is its high 
thermal stability. The thermal stability of human hemoglobin is known to be fairly 
low and a tetrameric hemoglobin molecule is able to dissociate into its ap dimer 
subunits, even in mild solution conditions (e.g. neutral pH, low salt 
concentration, low temperature, etc.). Exposure to temperatures above 50 °C 
causes rapid (within minutes) irreversible denaturation with precipitation [9]. 
The analysis is based on a two-state model in which the protein is 
considered to be either in the native or denatured state [11-12]: N -- D, 
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where N and D represent the native state and the denatured state, respectively. 
This model assumes that the native protein structure unfolds in a cooperative 
manner: Any partial unfolding of the structure destabilizes the remaining 
structure, which must simultaneously collapse to the random coil [1 OJ. The 
transition can be characterized at any stage by a single variable fo, the fraction 
of molecules in the denatured state. If y represents the experimental variable 
being used to follow the transition, and YN and Yo are the characteristic values of 
y for the initial and final states, we have the following equation: 
Y = YN + fo(Yo - YN), or 
In the UVNis spectral method [13], absorbance A is used as the experimental 
variable. Therefore, the equation is converted to: 
The thermal denaturation transition Tm can be obtained by the first-
derivative method which calculates the slope of the absorbance versus 
temperature (dAtdn. The minima of the dA/dT versus temperature at which the 
absorbance is changing most rapidly are Tm's. 
Autoxidation of Hemoglobin 
A normal physiological function of hemoglobin is the reversible binding of 
oxygen which can only occur with the heme iron in the reduced state (Fe(ll)). 
Although hemoglobin in red blood cells is slowly oxidized to methemoglobin 
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(Fe(lll)) at a rate of about 3% per day, the level of methemoglobin in the body 
remains constant at 1 % because whenever methemoglobin forms in red cells, it 
is readily reduced to ferrohemoglobin by an enzymatic system, methemoglobin 
reductase and NADH-cytochrome bs reductase [14-15]. Outside the 
erythrocytes, the amount of methemoglobin can not be minimized by enzymes. 
The oxidation of hemoglobin decreased significantly when anti-oxidant enzymes 
such as catalase and superoxide dismutase (SOD) were present with 
hemoglobin [16-17]. The autoxidation may result in hemichrome formation, 
protein denaturation, Heinz body formation and other changes [18-19]. 
The autoxidation rate of hemoglobin is influenced by many factors, such 
as pH value, oxygen pressure, temperature, and BPG concentration [20-22]. 
The fact that the autoxidation reaction is favored by BPG or inositol 
hexaphosphate (IHB) suggests that deoxyhemoglobin is faster to autoxidize than 
oxyhemoglobin. 
The oxyhemoglobin and methemoglobin concentrations (mM) can be 
calculated using the following equations: 
[Oxyhemoglobin] = 66As11 - 80As30 
[Methemoglobin] = 279As30 - 3Asn 
However, in most cases, the reaction is more complicated. The autoxidation 
can cause other changes, such as the formation of hemichrome which is a 
common intermediate in various types of hemoglobin denaturation (23-25] or 
generation of other denatured derivatives, e. g., choleglobin. Subtracting A700 -
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0.005, as the contribution of choleglobin, from each of the other absorbances, 
the concentrations of oxyhemoglobin, methemoglobin and hemichrome can be 
calculated using these equations: 
[Oxyhemoglobin] = 119As11 - 39A630 - 89A550 
[Methemoglobin] = 28As11 + 307 A630 - 55A550 
[Hemichrome] = -133As11 -114A630 + 233A560 
The mechanism of the autoxidation reaction is a complex process. It is 
found that the autoxidation is a pseudo-first order reaction dependent upon the 
concentration of hemoglobin, ligand and period of time [26]. The most plausible 
reaction route for the autoxidation is described as following [27]: 
2Hb~ Hemin + globin 
irreversible __ .,., precipitate 
hemichromes (red cell lysis) 
The apparant rate constant of hemoglobin autoxidation, kapp, can be obtained 
by calculation of the slope of the logarithms of oxyhemoglobin concentration as 
a function of time. The half life time of oxyhemoglobin in autoxidation, fo2, is 
calculated as following: 
fo2 = ln2/kapp 
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Hemoglobin-Based Blood Substitutes [28-29] 
Hemoglobin in solution has the capability to transport oxygen and, 
theoretically, could be used as a substitutes for red cells. Since hemoglobin 
solutions are oncotically active, they can also expand plasma volume. These 
properties would be desirable for a resuscitation fluid when rapid initial treatment 
of hypovolemia and tissue hypoxia is required. As a resuscitation fluid, 
hemoglobin must be able to maintain tissue oxygenation for a specified period of 
time. There are no well-defined physiological criteria to help quantify the effects 
of an oxygen-transporting hemoglobin. Ideally, hemoglobin solution should 
have the same capability to maintain tissue oxygenation as blood. 
The concept of using hemoglobin as a blood substitute is not new [30] but 
renal toxicity limited its development. In recent years, the interest in the 
development and evaluation of hemoglobin solutions as a blood substitutes has 
intensified [31]. With increasing knowledge and better understanding of 
hemoglobin, a clearer picture has been achieved concerning the capabilities 
and limitations of this potential oxygen-transporting fluid, as well as the 
manipulations that may overcome these limitations. 
Some of the limitations of unmodified hemoglobin solution are easily 
defined. (1) Hemoglobin transports oxygen as a ligand that requires heme and 
globin. The reversible binding of oxygen requires interaction between four 
chains of hemoglobin, i.e. cooperativity, which results from the ability of the 
protein to exist as two different quaternary structure (relaxed and tense) that 
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have different oxygen affinities [32]. Cooperativity allows hemoglobin to on-load 
oxygen when the oxygen tension is high (approximately 100 mmHg p02) and to 
off-load oxygen when the oxygen tension is low (approximately 40 mmHg p02) 
and gives rise to the sigmoidal shape of the oxygen-hemoglobin dissociation 
curve. Hemoglobin in solution has a higher oxygen affinity (lower Pso) than 
intraerythrocytic hemoglobin [33]. The tense state of hemoglobin in red cells is 
stabilized by the presence of organic phosphates such as BPG [34]; the tense 
state of hemoglobin is not stabilized since 2,3-BPG is absent and, therefore, 
hemoglobin in solution has a lower Pso (13-16 mmHg). (2) Aqueous hemoglobin 
exists in equilibrium between the tetrameric (MW 64,000) and dimeric (MW 
32,000) forms [35]. The dimers are readily excreted by the kidneys and results 
in rapid intravascular elimination of hemoglobin solution (2-4 hour plasma half-
disappearance). (3) Since hemoglobin is a colloidal-active protein, it in solution 
exerts a colloid oncotic pressure which limits it to a lower concentration (7 g/dl) 
of hemoglobin compared to the intra-erythrocytic concentration (30 g/dl) [36]. 
To overcome the limitations inherent to hemoglobin, it can be modified by 
biotechnology [37-38] and/or chemistry. In chemistry, two basic approaches 
have been used: (1) Molecular modification; (2) Environmental modification. 
Molecular modification requires the stabilization of hemoglobin to prevent dimer 
formation and maintenance of the tense conformational state. To do this, 
hemoglobin has to be crosslinked and this topic is discussed in detail in the next 
section on Crosslinking of Hemoglobin. Environmental modification requires 
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hemoglobin encapsulation to simulate erythrocytes. If hemoglobin and BPG 
could be encapsulated, then hemoglobin could be maintained in the tense 
conformational state. If the encapsulation material was biologically similar to 
erythrocytes, then longer intravascular retention than unmodified hemoglobin 
would occur. Encapsulation of hemoglobin was shown by Chang [39-43) to be 
feasible but the physicochemical properties of capsules did not allow the 
material to circulate. The studies by Djordjevich and Miller [44) and Hauser et al. 
[45) suggested that liposomal micelles may provide physicochemical properties 
that are biologically acceptable. 
Crosslinking of Hemoglobin 
There have been three approaches to 
crosslinking: (1) intermolecular (between two 
or more hemoglobins), (2) intramolecular 
(within one hemoglobin tetramer) and, (3) Bis(N-maleimidomethyl) ether 
hemoglobin-macromolecular (hemoglobin to a 
non-excretable macromolecule, such as dextran [46-
49) and polyethylene glycol [50-51 ]). Glutaraldehyde 
Crosslinking hemoglobin was shown, by Bunn 
and Jandl [35), to reduce renal elimination and increase intravascular retention. 
The reagent they used, bis(N-maleimidomethyl) ether, did allow conformational 
changes; their derivative had a high oxygen affinity (P50 = 3 mmHg). Most of the 
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crosslinking reagents used have reacted with amino groups of hemoglobin. 
Since the ap dimer has 22 primary amino groups which can react, the functional 
group specificity is insufficient to give homogeneity. Thus, using glutaraldehyde 
[52-57] or imidoesters [58] to crosslink hemoglobin produces heterogeneous 
products. 
Benesch et al [59] showed that pyridoxal 5-phosphate had an analogous 
effect to BPG to lower affinity (Pso = 26-30 mmHg); it binds covalently to 
hemoglobin, unlike BPG, but does not act as a 
0 
0 8-H crosslinking reagent. The discovery of a specific 
Benesch [60] led to the description of a variety of 
HO-ILo-cK,z'():OH AH I 
~ CHa 
hemoglobin crosslinker by Ruth and Reinhold 
modifications of hemoglobin which not only reduce 
Pyridoxal 5-phosphate 
their oxygen affinity but also stabilize the tetrameric structure so that their 
vascular retention can be prolonged. In 1975, Benesch et al. [61] used 2-nor-2-
formylpyridoxal-5' -phosphate (NFPLP) to react with deoxyhemoglobin and, after 
reduction with sodium borohydride, to form a covalent bridge between /J1Val1 
and ,BiLys82. The negative charge from the phosphate group of the pyridoxal 
compound has an electrostatic interaction with positive charges from the amino 
acid residues in the BPG cleft. This effect stabilized the T state which mimics 
closely the effect of BPG on hemoglobin [62-64]. In 1988, Benesch and Kwong 
[65-66] also developed a new class of bis-pyridoxal polyphosphate compounds 
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to crosslink deoxyhemoglobin between the amino terminus of a ~chain and the 
lysine 82 of the other ~chain, as in the case using NFPLP. 
Klotz and his co-workers synthesized a series of diaspirin compounds, 
such as bis(3,5-dibromosalicyl) fumarate (DBSF), succinate (DBSS), glutarate 
(DBSG) and adipate (DBSA) during 1975 and 1979 [67-68]. The dibromosalicyl 
ether compounds are more specific in their reactions. Walder and his co-
workers showed that DBSF reacts with 
-Q-Br 0 H ~ Br o-~ ... < p C C- Br 
COH K A 
I Br 0 
oxyhemoglobin to crosslink between 
P1Lys82 and Pzlys82 [69]. However, 
DBSF crosslinks between the two Lys99 
Bis(3,5-dibromosalicyl) fumarate 
of the a chains when it reacts with 
deoxyhemoglobin [70]. White, Yang and Olsen [71-72] used DBSF to stabilize 
hemoglobin thermally. Huang and Olsen [73] used DBSS and DBSG to crosslink 
met-, oxy- and deoxyhemoglobin. The added flexibility of these reagents results 
in a more heterogeneous product but does not greatly affect the maximum 
thermal stability of the crosslinked hemoglobins. 
Kluger et al. [7 4-77] synthesized a series of bis methyl acetyl phosphate 
(MAP) acetylation agents, and showed that the reagents only reacts with Val1, 
Lys82 and Lys144 of the p chains. 
Kluger et al. synthesized two tri-
linkers: trimesoyl tris{3,5-
dibromosalicylate) (TTDS) [78] whose 
reaction with deoxyhemoglobin is highly 
0 0 I I _ 
o o-Qc-o-~-o 
_ I I OCH3 
O-P-0-C 
I 
OCH3 ?CH~ 
C-O-P-0 
I I 
0 0 
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selective for the filys82 residues and the Trimesoyl tris(methyl phosphate) 
third active ester group reacts much more slowly, principally undergoing 
hydrolysis; and trimesoyl tris(methyl phosphate) (TTMP) [79] which is selective 
to react between P1Val1 and fiilys82. The major species is tri-linked between 
Val1fi1, Lys82P1 and Lys82fii, and both tri- and bi-linked species produced from 
deoxyhemoglobin have a considerably lower oxygen affinity than does native 
hemoglobin while maintaining a high degree of cooperativity. 
Work of the Dissertation 
For development of blood substitutes, a series of novel aspirin multi-
linkers were designed and synthesized for modification of hemoglobin in this 
dissertation. Anionic acylating reagents show selectivity for certain amino 
groups within hemoglobin, particularly those located in the site which binds the 
polyanionic regulator BPG. In addition to electrostatic effects, selectivity and 
efficiency can be enhanced by taking advantage of steric effects which play an 
important role in determining the regioselectivity of organic reagents. Such 
effects can increase the selectivity of a protein reagent. According to this 
principle, computer modeling techniques [78] were utilized to model 3-
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dimensional structures of hemoglobin A molecules and hemoglobin crystal unit 
cells, measure distances between amino groups of lysine or other residues, 
indicate possible sites of crosslinking reactions and design the reagents with 
sizes, shapes and polarities that fit the specific reactive sites in hemoglobin A 
Bulky multifunctional reagents possess the selectivity for reaction on 
specific-sites in a protein due to steric effects and electrostatic interaction. 
However, the reaction of 3,5-dibromosalicylic acid with aromatic carboxylic acid 
chlorides, or with acid chlorides expected to form bulky reagents, gives a very 
low yield of the desired products in the presence of a tertiary amine as the 
catalyst. The method developed by Klotz involving protection of the carboxyl 
group of 3,5-dibromosalicylic acid as the tert-butyl ester, coupling, and 
deprotection [81 ], was used successfully to produce a good yield of the desired 
products. However, the preparation of tert-butyl 3,5-dibromosalicylate has not 
been mentioned in any related publication. Based on the successful synthesis 
and purification of tert-butyl salicylate, tert-butyl 3,5-dibromosalicylate was 
made using N, N'-dicyclohexylcarbodiimide (DCC) to couple tert-butyl alcohol 
and 3, 5-dibromosalicylic acid. 
The reagents successfully synthesized for reaction with hemoglobin in the 
BPD binding site include: bis(3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) 
dibenzoate, bis(3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether, 
tris(3, 5-dibromosal icy I) tricarballylate, tris(3, 5-dibromosal icy I) (3, 5-dicarboxy 
phenoxy) acetate, tetrakis(3,5-dibromosalicyl) 5,5'-(1,3-propanedioxy) 
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diisophthalate, tetrakis(3,5-dibromosalicyl) 5, 5' -triethyleneglycol diisophthalate 
ether and tetrakis(methyl phosphate) 5,5'-(1, 10-decanedioxy) diisophthalate. 
The tri-linkers were designed to get multi-linking of intrahemoglobin and the long 
bi- and tetra-linkers to crosslink interhemoglobins. 
The reaction of hemoglobin with the tri-linkers gave both double and tri-
linking as major products. Double-, tri- and tetra-crosslinking were found in 
reaction of hemoglobin with the tetra-linkers. The mechanism of crosslinking 
reaction of proteins with an aspirin crosslinker is as follows: 
~ 9 
/ \ HOC 
Protein-NH2 + Linker-C-09-'\ Br -
.(II -0 
Br 
0 
II 
HOC 
Link~r 
Protein-NH-t ~ f '\ Br ~~ t:b:· -
Br 
l 
0 0 II (\II 
0 H9-0C H+ PHOC Protein-NH-~-Linker + HO f '\ Br - Protein-NH-C-Linker + o· f '\ Br 
- b -
Br Br 
and that of crosslinking reaction of proteins with a methyl phosphate crosslinker 
as follows: 
~ ~ONa 
Protein-NH2 + Linker-c-o-p" {8 '0CH3 
! 
0 0 II 11,.0H 
Protein-NH-C-Linker + NaO-P, 
OCH3 
We also studied crosslinking in hemoglobin crystals. Oxygen-binding, 
denaturation and autoxidation of isolated crosslinked hemoglobins were 
measured and compared with those of native hemoglobin. 
Chapter 2 
MATERIALS AND EXPERIMENTS 
Chemicals and Other Materials 
Methanol, ethanol, tetrahydrofuran (THF), acetone, diethyl ether, hexane, 
tert-butyl alcohol, 3,5-dibromosalicylic acid, 1.3-dicyclohexylcarbodiimide (DCC), 
bromoacetic acid, 1,3-dibromopropane, 1,2-bis(2-iodoethoxy) ethane, 4-
hydroxybenzoic acid, 5-hydroxyisophthalic acid, tricarballylic acid, trimethyl 
phosphate, thionyl chloride, N,N-dimethylformamide (DMF), trifluoroacetic acid 
(TFA), glacial acetic acid, silica gel, chloroform-d3 (CDCl3), dimethyl sulfoxide-d6 
(DMSO-d6) were purchased from Aldrich Chemical Co., Inc.; inorganic 
chemicals: anhydrous magnesium sulfate, anhydrous sodium sulfate, calcium 
hydride, potassium metal, hydrochloric acid, sodium iodide from Stansi Scientific 
Co.; DEAE-Sephadex A-50 gel, SDS homogeneous gel, SDS low molecular 
weight markers, SDS buffer strips, Blue R, from Pharmacia Fine Chemicals; 
tris(hydroxymethyl aminomethane hydrochloride (Tris), 4-morpholinepropane 
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sulfonic acid (MOPS), Sephadex G-25 gel, from Sigma Chemical Co.; sodium 
cyanide, ammonium sulfate, urea, sodium phosphate, sodium hydroxide from J. 
T. Baker Chemical Co.; potassium ferricyanide, sodium chloride from 
Mallinckrodt, Inc.; guanidine hydrochloride, sodium dodecylsulfate, from Pierce 
Chemical Co.; p-mercaptoethanol from CalBiochem.; alkaline agarose gels 
from Corning Medical; 02 Probe solution, electrode membrane from YSI 
Incorporated; TLC silica gel plates, filter paper from Whatman Ltd .. 
Instruments 
Crosslinkers were synthesized using an electrical heating mantle, 
magnetic stirrer and BUCHI rotary-evaporator. Identification of synthetic organic 
compounds was ascertained by recording NMR spectra using a Varian VXR 300 
MHz NMR Spectrometer, infrared spectra using an ATI Mattson FTIR, and 
melting points were determined using a Mel-TEMP. Preparation of hemoglobin 
was carried out using a Sorvall RC-58 Refrigerated Superspeed Centrifuge, 
hemoglobin A and hemoglobin A2 were separated through a Sephadex A-50 ion-
exchange column with an ISCO UA-5 absorbance/fluorescence detector, ISCO 
Tris pump and ISCO fraction collector, and purity of hemoglobin was determined 
using Cornning ACI clinical gel. Reaction of hemoglobin with crosslinking 
reagents was carried out in water bath. Concentration, denaturation and 
autoxidation of native hemoglobin and crosslinked hemoglobins were tested 
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using a Hewlett-Packard (HP) 8452A UVNIS Diode Array Spectrophotometer 
with a PC computer Model 386, Endocal Refrigerated Circulating Bath RTE-9, 
DCR-4 Digital Controller/Readout and Omega temperature indicator. Oxygen-
binding of blood, hemoglobin and crosslinked hemoglobins was conducted using 
a Hemox-analyzer Model B with a plotter. Crosslinked hemoglobins were 
analyzed using a Pharmacia SOS Slab Gel Electrophoresis Unit SE250 with an 
ISCO Gel Scanner Model 1312. Buffer solutions were prepared using an Orion 
research digital pH meter. Hemoglobin was concentrated using an Amicon 
Microconcentrator. Computer modeling was done using an Iris Indigo Silicon 
Graphics with an Insight II/Discover software from Biosym. 
Experiments 
Synthesis of terl-butyl salicylate (see Scheme I) 
2.10 g (0.01 mol) of 1,3-dicyclohexylcarbodiimide (DCC) dissolved in 5 ml of 
tert-butyl alcohol was added slowly into the solution of 1.38 g (0.01 mol) of salicylic 
acid in 5 ml of tert-butyl alcohol. The reaction mixture was stirred at room 
temperature for 3 h. The white precipitate (dicyclohexylurea, DCU) was removed 
by suction filtration. The filtrate was concentrated by a rotary-evaporator. The 
residue was separated by a silica gel column with methylene chloride as eluent. The 
product obtained was a liquid with a strong fruity odor. 
Synthesis of terl-butyl 3,3-dibromosalicylate (see Scheme II) 
Scheme I. 
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5.1 g (0.025 mol) of DCC in 50 ml of tert-butyl alcohol was added into the 
solution of 5.9 g (0.02 mol) of 1,3-dibromosalicylic acid in 50 ml of tert-butyl alcohol. 
The reaction mixture was stirred at room temperature for 5 h. The white precipitate 
(DCU) was filtered off by suction and the excess tert-butyl alcohol was removed by a 
rotary-evaporator. The residue was recrystallized from ethanol and 4.5 g of white 
needle crystals were obtained (yield: 63.9%). 
Synthesis of bis(3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) dibenzoate 
(see Scheme Ill) 
4,4'-(1,3-Propanedioxy) dibenzoic acid. 2.02 g (0.01 mol) of 1,3-dibromopropane 
dissolved in 15 ml of methanol was added in the solution of 2.76 g (0.02 mol) of 4-
hydroxybenzoic acid and 2.0 g (0.05 mol) of sodium hydroxide in 15 ml of water. 
The reaction mixture was refluxed overnight to get a homogeneous solution. The 
methanol was removed by a rotary-evaporator. The remaining aqueous solution 
was filtered and acidified with 6 N hydrochloric acid. The precipitate was collected 
by suction filtration and washed with water. 1.66 g of the product was obtained 
(yield: 52.5%). 
4,4'-(1,3-Propanedioxy) dibenzoyl chloride. 0.5 g (1.58 mmol) of 4,4'-(1,3-
propanedioxy) dibenzoic acid and then 1 drop of dimethylformamide (DMF) were 
added into 5 ml of thionyl chloride (distilled). The mixture was refluxed overnight 
with stirring and a drying trap. The excess thionyl chloride was removed by 
distillation and the residue was recrystallized from hexane to get white crystals (yield: 
45.3%). 
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Bis(tett-butyl 3,5-dibromosalicylate) 4,4'(1,3-propanedioxy) dibenzoate. 1.1 O g 
(3.12 mmol) of tert-butyl 3,5-dibromosalicylate and 0.35 g (3.12 mmol) of potassium 
tert-butoxide were stirred in 30 ml of tetrahydrofuran (THF) (distilled over calcium 
hydride) for 30 min at room temperature. 0.61 g (1.58 mmol) of 4,4'-(1,3-
propanedioxy) dibenzoyl chloride dissolved in 10 ml of THF was added into the 
mixture and stirred overnight at room temperature. The THF was removed by a 
rotary-evaporator. Diethyl ether was added for extraction and the ether was 
subsequently washed with water. The organic layer was dried over anhydrous 
Na2S04 and concentrated by a rotary-evaporator. The residue was recrystallized 
from ethanol (yield: 51.2%). 
Bis(3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) dibenzoate. 0.10 g of bis(tert-
butyl 3,5-dibromosalicylate) 4,4'-(1,3-propanedioxy) dibenzoate was dissolved in 2 
ml of trifluoroacetic acid (distilled) and kept in an ice bath for 1 h. 2 ml of diethyl 
ether (distilled over CaH2) was added in the solution and the mixture was kept at 4°C 
overnight. The precipitate was filtered and dried by suction and 0.05 g of white 
powder product was obtained (yield: 58.1%). 
Synthesis of bis(3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether 
(see Scheme IV) 
4,4'-Triethyleneglycol dibenzoic acid ether. 3.07 g (0.01 mol) of 1,2-bis(2-
iodoethoxy) ethane in 10 ml of methanol were added into the solution of 2.76 g 
(0.02 mol) of 4-hydroxybenzoic acid and 2.0 g (0.05 mol) sodium hydroxide 
dissolved in 1 O ml of water. The reaction mixture was refluxed overnight to get a 
Scheme IV. 
0 
2Ho-Q-80H + 
! NaOHIH:zO 
KOC(CH3)31 TDBS 
0 0 
II II 
31 
(CH3)3C-O-C C-0-C(C~h 
Br--Q-o-~-Q-o-cH,CH20CH,CH,OCH,CH,-o-0-tpBr 
Br Br 
!CF380H 
0 0 
II II 
COH HOC 
Br--Q-J-o-o-cH,CH,OCH,CH,OCH,CH,--o--Ql-Par 
& & 
32 
homogeneous solution. The methanol was removed by a rotary-evaporator. The 
remaining aqueous solution was filtered and acidified with 6 N hydrochloric acid. 
The precipitate was collected by suction filtration and washed with water. 1.60 g of 
product was obtained (yield: 41.0%). 
4,4'-Triethyleneglycol dibenzoyl ether chloride. 0.3 g (0.768 mmol) of 4,4'-
triethyleneglycol dibenzoic acid ether and 1 drop of DMF were added in 4 ml of 
thionyl chloride (distilled). The mixture was refluxed overnight with stirring and a 
drying trap. The excess thionyl chloride was removed by distillation and the residue 
was dried in a fume hood (yield: 43.5%). 
Bis(tert-butyl 3,5-dibromosalicylate) 4,4'-triethyleneglycol dibenzoate ether. 
0.49 g (1.39 mmol) of tert-butyl 3,5-dibromosalicylate and 0.15 g (1.34 mmol) of 
potassium tert-butoxide in 8 ml of THF (distilled over calcium hydride) were stirred 
for 30 min at room temperature. 0.298 g (0.65 mmol) of 4,4'-triethyleneglycol 
dibenzoyl chloride ether in 1 O ml of THF was added into the mixture and stirred 
overnight at room temperature. The THF was removed by a rotary-evaporator. 
Diethyl ether was added to extract and the ether layer was subsequently washed 
with water. The organic layer was dried over anhydrous Na2S04 and concentrated 
by a rotary-evaporator. The residue was recrystallized from ethanol (yield: 47.9%). 
Bis(3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether. 0.1 g of bis(tert-
butyl 3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether was dissolved in 2 
ml of trifluoroacetic acid and kept in an ice bath for 1 h. 2 ml of diethyl ether was 
added to the solution and the mixture was kept at 4 °C overnight. The precipitate 
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was filtered and dried by suction and 0.04 g of white powder was obtained (yield: 
45.8%). 
Synthesis of tris(3,5-dibromosalicyl) tricarballylate (see Scheme V) 
Tricarballylyl trichloride. 2.2 g (0.0125 mol) of tricarballylic acid and 5 drops of 
DMF were added into 25 ml of thionyl chloride (distilled). The mixture was refluxed 
overnight with stirring and a drying trap. The excess thionyl chloride was removed 
by distillation. The residue was purified by vacuum distillation at 117-119°C (4.2-4.3 
mm Hg) to give 2.1 g of liquid product (72.6% yield). 
Tris(tett-butyl 3,5-dibromosalicylate) tricarballylate. 0.92 g (2.60 mmol) of tert-
butyl 3,5-dibromosalicylate and 0.25 g (2.61 mmol) of potassium tert-butoxide in 10 
ml of THF (distilled over CaH2) were stirred for 30 min at room temperature. 0.20 g 
(0.65 mmol) of tricarballylyl trichloride in 5 ml of THF was added to the mixture, 
which was subsequently stirred overnight at room temperature. The THF was 
removed with a rotary-evaporator. The residue was extracted by diethyl ether and 
the ether layer was then washed with water. The organic layer was dried over 
anhydrous Na2S04 and concentrated with a rotary-evaporator. The residue was 
recrystallized from ethanol (yield: 50.7%). 
Tris(3,5-dibromosalicyl) tricarballylate. 0.1 g of tris(tert-butyl 3,5-dibromosalicyl) 
tricarballylate was dissolved in 2 ml of trifluoroacetic acid (distilled) and kept in an 
ice bath for 1 h. 2 ml of diethyl ether was added to the solution and the mixture was 
kept at 4 °C overnight. The precipitate was filtered and dried by suction and 0.07 g 
of white powder was obtained (yield: 80%). 
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Synthesis of Tris(3, 5-dibromosalicyl) 5-acetate isophthatate ether 
(see Scheme VI) 
35 
(3,5-Dicarboxy phenoxy) acetic acid. 3.64 g (0.02 mol) of 5-hydroxyisophthalic 
acid, 2.78 g (0.02 mol) of bromoacetic acid and 4.0 g (0.10 mol) of sodium 
hydroxide were dissolved in 50 ml of water and the mixture was then refluxed 
overnight. The reaction mixture was filtered and acidified with 6 N hydrochloric 
acid. The precipitate was collected by suction filtration and washed in 
succession with water and acetone. 3.0 g of the product was obtained (yield: 
62.5%). 
(3,5-Dicarboxy phenoxy) acetyl trichloride. 0.5 g (2.08 mmol) of (3,5-
dicarboxy phenoxy) acetic acid and 2 drops of DMF were added to 1 O ml of 
thionyl chloride (distilled) and the mixture was refluxed with stirring and a drying 
trap overnight. The excess SOCl2 was removed by distillation. The residue was 
recrystallized from hexane and the product was yielded 0.27 g of white crystals 
(43.9% yield). 
Tris(terl-butyl 3, 5-dibromosalicylate) (3,5-dicarboxy phenoxy) acetate. 0.54 
g (1.5 mmol) of terl-butyl 3,5-dibromosalicylate and 0.36 g (1.5 mmol) of 
potassium tert-butoxide were stirred in dry THF (distilled over CaH2) for 30 min 
at room temperature. 0.15 g (0.5 mmol) of (3,5-dicarboxy phenoxy) acetyl 
trichloride dissolved in 4 ml of THF was added into the mixture, which was 
subsequently stirred overnight at room temperature. The THF was removed with 
a rotary-evaporator. The residue was extracted with diethyl ether and was washed 
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with water. The organic layer was dried over anhydrous Na2S04 and concentrated 
by a rotary-evaporator. The residue was recrystallized from ethanol (0.31 g, 49.2% 
yield). 
Tris(3, 5-dibromosalicyl) (3,5-dicarboxy phenoxy) acetate. 0.3 g of tris(tert-
butyl 3,5-dibromosalicyl) (3,5-dicarboxy phenoxy) acetate was dissolved in 2 ml 
of trifluoroacetic acid (distilled) and kept in an ice bath for 1 h. 2 ml of diethyl 
ether was added to the solution and the mixture was kept at 4°C overnight. The 
precipitate was collected by suction filtration and 0.22 g of product was obtained 
(84.8% yield). 
Synthesis of tetrakis(3,5-dibromosalicyl) 5,5'-(1,3-propanedioxy) 
diisophthalate (see Scheme VII) 
5,5'-(1,3-Propanedioxy) diisophthalic acid. 2.01 g (0.01 mol) of 1,3-
dibromopropane in 15 ml of methanol was added to the solution of 3.64 g (0.02 
mol) of 5-hydroxyisophthalic acid and 3 g (0.075 mol) of sodium hydroxide in 15 ml 
of water. The reaction mixture was refluxed overnight to get a homogeneous 
solution. The methanol was removed with a rotary-evaporator. The remaining 
aqueous solution was filtered and acidified with 6 N hydrochloric acid. The 
precipitate was collected by suction filtration and washed with water. 1.88 g of 
product was obtained (46.5% yield). 
5,5'-(1,3-Propanedioxy) diisophthalyl tetrachloride. 0.25 g (0.618 mol) of 5,5'-
(1,3-propanedioxy) diisophthalic acid and 1 drop of DMF were added to 3 ml thionyl 
chloride (distilled) and the mixture was refluxed with stirring and a drying trap 
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overnight. The excess thionyl chloride was removed by distillation and the residue 
was recrystallized from hexane to get white crystals (48.6% yield). 
Tetrakis( ten-butyl 3,5-dibromosalicylate) 5,5'-(1,3-propanedioxy) diiso-
phthalate. 0.6 g (1.6 mmol) of tert-butyl 3,5-dibromosalicylate and 0.18 g (1.6 mmol) 
of potassium tert-butoxide in 25 ml of THF (distilled over calcium hydride) were 
stirred for 30 min at room temperature. 0.27 g (0.40 mot) of 5,5'-(1,3-propanedioxy) 
diisophthalyl tetrachloride in 50 ml of THF was added into the mixture and stirred 
overnight at room temperature. The THF was removed with a rotary-evaporator. 
The residue was extracted with diethyl ether. The ether layer was washed with 
water and dried over anhydrous Na2S04 and concentrated by a rotary-evaporator. 
The residue was recrystallized from ethanol (50.3% yield). 
Tetrakis(3,5-dibromosalicyl) 5,5'-(1,3-propanedioxy) diisophthalate. 0.1 g of 
tetras(tert-butyl 1,3-dibromosalicylate) 5,5'-(1,3-propanedioxy) diisophthalate was 
dissolved in 2 ml of trifluoroacetic acid (distilled) and kept in an ice bath for 1 h. 2 
ml of diethyl ether was added to the solution and the mixture was kept at 4 °C 
overnight. The precipitate was filtered and dried by suction and 0.07 g of white 
powder product was obtained (83.5% yield). 
Synthesis of tetrakis(3,5-dibromosalicyl) 5,5'-triethyleneglycol 
diisophthalate ether(see Scheme VIII) 
5,5'-Triethyleneglycol diisophthalic acid ether. 3.70 g (0.01 mol) of 1,2-bis(2-
iodoethoxy) ethane in 15 ml of methanol was added into the solution of 3.64 g (0.02 
mol) of 5-hydroxyisophthalic acid (0.02 mol) and 3.0 g (0.075 mot) of sodium 
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hydroxide in 15 ml of water. The reaction mixture was refluxed overnight to get a 
homogeneous solution. The methanol was removed with a rotary-evaporator. The 
remaining aqueous solution was filtered and acidified with 6 N hydrochloric acid. 
The precipitate was collected by suction filtration and washed with water. 1. 75 g of 
the product was obtained (36.6% yield). 
5,5'-Triethyleneglycol diisophthalyl ether tetrachloride. 0.2 g (0.418 mol) of 5,5'-
triethyleneglycol diisophthalic acid ether and 1 drop of DMF were added into 4 ml of 
thionyl chloride (distilled). The mixture was refluxed overnight with stirring and a 
drying trap. The excess thionyl chloride was removed by distillation and the residue 
was recrystallized from hexane to obtain white crystals. 
Tetrakis( tert-butyl 3,5-dibromosalicylate) 5,5'-triethyleneglycol diisophthalate 
ether. 0.69 g (1.96 mmol) of tert-butyl 3,5-dibromosalicylate and 0.21 g (1.96 mmol) 
of potassium tert-butoxide in 10 ml of THF (distilled over calcium hydride) were 
stirred for 30 min at room temperature. 0.237 g (0.475 mmol) of 5,5'-
triethyleneglycol diisophthalyl ether tetrachloride in 10 ml of THF was added into 
the mixture, which was then stirred overnight at room temperature. The THF was 
removed with a rotary-evaporator. Diethyl ether was added for extraction. The ether 
layer was washed with water and dried over anhydrous Na2S04 and concentrated by 
a rotary-evaporator. The residue was recrystallized from ethanol. 
Tetrakis(3,5-dibromosalicyl) 5,5'-triethyleneglycol diisophthalate ether. 0.1 g of 
tetrakis(t-butyl 3,5-dibromosalicylate) 5,5'-triethyleneglycol diisophthalate ether was 
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dissolved in 2 ml of trifluoroacetic acid (distilled) and kept in an ice bath for 1 h. 2 
ml of diethyl ether was added to the solution and the mixture was kept at 4 °C 
overnight. The precipitate was filtered and dried by suction and 0.7 g of white 
powder product was obtained (58.1 % yield). 
Synthesis of tetrakis(methyl phosphate) 5,5'-(1,10-decanedioxy) 
diisophthalate (see Scheme IX) 
5,5'-(1,10-decanedioxy) diisophthalic acid. 3.94 g (0.01 mol) of 1, 10-
diiododecane in 10 ml of dimethyl sulfoxide (DMSO) was added into 3.64 g (0.02 
mol) of 5-hydroxyisophthalic acid and 3 g (0.075 mol) of sodium hydroxide dissolved 
in 1 o ml of water. The mixture was stirred and refluxed overnight. 50 ml of water 
was added to dissolve the mixture. The solution was filtered and acidified with 6 N 
hydrochloric acid. The precipitate was collected by suction filtration and washed with 
hot water. 2.5 g of the desired product was obtained (50 % yield). 
5,5'-(1,10-decanedioxy) diisophthalate tetrachloride. The mixture of 0.5 g of 
5,5'-( 1, 10-decanedioxy) diisophthalic acid and 5 ml of thionyl chloride was stirred 
and refluxed in the presence of 1 drop of DMF for 2 days. The excess SOCl2 was 
removed by distillation and the residue was recrystallized from dry acetone which 
yielded 0.23 g (40 % yield). 
Tetrakis(dimethyl phosphate) 5,5'-(1,10-decanedioxy) diisophthalate. 0.30 g of 
5,5'-(1,10-decanedioxy) diisophthalate tetrachloride in 2 ml of dry THF was added 
to the mixture of 0.34 g of sodium dimethyl phosphate in 3 ml of dry THF. The 
mixture was stirred in an ice bath for 3 h. The precipitate was removed by suction 
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filtration and the filtrate was concentrated with a rotary-evaporator to obtain a 
yellowish oil. 
Tetrakis(sodium methyl phosphate) 5,5'-(1,10-decanedioxy) diisophthalate. 
0.35 g of sodium iodide dissolved in 2.5 ml of dry acetone was added to the oily 
residue dissolved in 2.0 ml of dry acetone. The mixture was stirred at room 
temperature overnight with protection from light. The precipitate was collected by 
suction filtration and washed with hot acetone. 0.23 g of product was obtained. 
Preparation of hemoglobin 
Hemoglobin A was isolated from packed red blood cells (RBC's), obtained 
from Life Source, following the procedure of Dozy et al. [82]. 80 ml of ice cold 
phosphate buffer saline (PBS: 150 mM NaCl in 5 mM phosphate buffer, pH 8.0) 
was added to 20 ml of red blood cells (RBC's). The mixture was stirred gently to be 
well mixed and centrifuged at 3000 rpm (1075 g) for 10 min with a Sorvall RC5B 
refrigerated superspeed centrifuge using an SS-34 rotor. The supernatant and buffy 
coat were removed by aspiration. The washing of the RBC's with PBS was 
repeated another two times to make sure that the RBC's were free of unwanted 
plasma materials. All these steps were performed at 4 °C. The washed 
erythrocytes were lysed in 40 ml of ice cold deionized water with gentle stirring for 
30 min in an ice bath. Then 20 ml of ice cold neutral saturated ammonium sulfate 
was added to the mixture and stirred for 2 h in an ice bath. Then the mixture was 
centrifuged at 12,000 rpm (17,210 g) for 10 min. The hemoglobin in the supernatant 
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was collected and the precipitate, containing membranes and other residues, was 
discarded. 
The hemolysate was desalted by dialysis against Tris buffer (0.05 M Tris, 1 
mM NaCN, pH 8.5). The completion of desalting was checked by adding 1 M BaCl2 
to the dialysis buffer solution to test if BaS04 precipitate was able to form. After 
desalting was complete, the dialysate was ready for ion-exchange chromatography. 
Ion-exchange chromatography was performed according to the methods of 
Huisman and Dozy [83], and Dozy et al. [82]. DEAE-Sephadex A-50 was swollen in 
deionized water. The column was packed with the Sephadex gel and equilibrated 
with a buffer composed of 0.05 M Tris, 1 mM NaCN, pH 8.5, at a flow rate of 
approximately 20 mUh at 4 °C. When the pH value of the eluent buffer reached 8.5, 
the dialyzed hemolysate was applied to the top of the column. Proteins were 
separated with a linear pH gradient from 8.5 to 7.2 with 0.05 M Tris, 1 mM NaCN. 
The elution was detected at 280 nm by a ISCO UA-5 absorbance/fluorescence 
detector. 
The purity of hemoglobin A was tested using clinical alkaline agarose gel 
electrophoresis (Corning Medical). The hemoglobin was concentrated by 
ultrafiltration over an Amico PM 10 membrane to the desired concentration. The 
concentration of hemoglobin and percentages of oxyhemoglobin, methemoglobin 
and hemichrome were determined spectrophotometrically on a HP 8452A UVNIS 
diode array spectrophotometer with a program written in QUICK BASIC version 4.5 
with QB LIBRARY revision 2.01 (see Appendix I (a)): The concentration of 
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hemoglobin is determined by using the extinction coefficient, ErrM, of 13.8 per heme 
at 542 nm [84] and the percentages of the components are obtained by calculating 
concentrations of oxyhemoglobin, methemoglobin and hemichrome [85]. The 
concentration of catalase is determined by using ErrM of 420 per tetramer at 405 nm 
[86]. 
Crystallization of hemoglobin 
In high salt concentration. Crystals of deoxyhemoglobin were grown by the 
method of Perutz [87]. The hemoglobin was dialyzed against 0.01 M ammonium 
phosphate buffer of pH 7.0 (8.5 ml of 2 M (NH4hHP04, 1.5 ml of 2 M NH4H2P04 
and 2 l deionized water). Crystallization was carried out at room temperature at a 
series of salt concentrations which pass through the critical point where 
crystallization begins. The optimum pH, buffer and hemoglobin concentrations are 
given in Table 1. 
Solution C, pH = 6.5, was made by mixing 0.8 volumes of 4 M (NH4hS04 
plus 0.05 volumes of 2 M (NH4)H2P04 plus 0.15 volumes of 2 M (NH4hHP04. 
Hemoglobin was at 6% (60 mg/ml HbA) to give a final concentration of 1 % in the 
crystallization setup. Sodium dithionite concentration was 1.25 M (5.44 g in 25 ml of 
deionized water made under nitrogen). 
The mixing of all solutions above was carried out in a glove bag filled with 
nitrogen gas. Crystallization setup was by the batch method. The vials with the 
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Table 1. Crystallization setup for high salt conditions. 
Sample Solution C* (µL) DI H20 (µL) 1.25 M Na2~04 (µL) 6% HbA(µL) 
1 698 37 15 150 
2 675 60 15 150 
3 653 82 15 150 
4 623 112 15 150 
5 600 135 15 150 
6 578 157 15 150 
7 563 172 15 150 
* See page 46. 
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above crystallization solutions were stored in nitrogen-filled desiccator jars sealed 
with greased ground glass lids. The crystals took over a week to grow. 
In low salt concentration. Crystals of deoxyhemoglobin were grown by the method 
of Ward et al. [88] and Arnone et al. [89]. Crystallization was from solutions that 
were 1% (10 mg/ml) in hemoglobin, 10 mM potassium chloride, 4 mM sodium 
dithionite and over a range of 9.5 to 10.75% PEG-6000. The actual volumes of the 
different solutions that were mixed are shown in Table 2. 
The mixing of all solutions above was carried out in a glove bag filled with 
nitrogen gas. Crystallization setup was by the batch method. The vials with the 
above crystallization solutions were stored in nitrogen-filled desiccator jars sealed 
with greased ground glass lids. The crystals took over two weeks to grow. 
Computer modeling 
The modeling of deoxyhemoglobin crystals and design of reagents were 
carried out using INSIGHT II software. For the modeling of deoxyhemoglobin 
crystals, the coordinate file of deoxyhemoglobin (2HHB) from the Protein DataBase 
(PDB) was converted into fit of the P21 space group by using a program written for 
the VAX-VMS 8530 main-frame (see Appendix II). A crystal unit of 
deoxyhemoglobin was modeled by using CELL, CELL_DISPLAY and 
MACRO_CELL in the ASSEMBLY command of INSIGHT. Another program was 
written for the VAX-VMS 8530 main-frame to make a model of deoxyhemoglobin 
crystal composed of six tetramers in INSIGHT II (see Appendix Ill). 
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Table 2. Crystallization setup for low salt conditions. 
Sample 0.1 M 1.25 M 25% PEG- 2 M P04 3- buffer 6%HbA 
KCI (µL) Na2S204 (µL) 6000 (µL) (µL) (µL) 
1 100 5 380 315 200 
2 100 5 390 305 200 
3 100 5 400 295 200 
4 100 5 410 285 200 
5 100 5 420 275 200 
6 100 5 430 265 200 
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Reagents were designed by using EDIT, 3D-STRUCTURE AND OPTIMIZE 
in BUILDER module of INSIGHT II. 
Crosslinking reaction of hemoglobin 
With tris(3,5-dibromosalicyl) tricarballylate. The reaction with tris(3,5-
dibromosalicyl) tricarballylate (DBSTC) was carried out in 0.01 M MOPS, 1 mM 
NaCN, at pH 7.0, essentially according to the method of Walder et al. [68] for 
oxyhemoglobin and of Chatterjee et al. [70] for deoxyhemoglobin. The concentration 
of hemoglobin was 0.55 mM and the molar ratio of hemoglobin tetramer to DBSTC 
was kept at 1 to 1.1 for all the experiments. 
The reaction with oxyhemoglobin was done by adding the calculated amount 
of DBSTC (powder) to the hemoglobin solution. The mixture was gently swirled 
every 30 min for a total of 3 h at 37 °C. Afterward, the reaction solution was 
submerged in an ice bath for 30 min to terminate the reaction. The hemoglobin 
solution was dialyzed in Tris buffer (pH 8.5) to get rid of small molecules and isolated 
through a DEAE-Sephadex A-50 column chromatography with a linear gradient of 
0.05 M Tris, 1 mM NaCN, pH 8.5 to 7.2. 
For the deoxyhemoglobin crosslinking reaction, the oxyhemoglobin solution 
was purged with a wet stream of nitrogen gas for at least 3 h in an ice bath until the 
solution was purplish. Then the solution was transferred to a water bath already 
equilibrated at 37 °C. The reagent, DBSTC , suspended in the buffer of 0.01 M 
MOPS, 1mM NaCN, pH 7.0 was injected into the hemoglobin solution. The 
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nitrogen purging was maintained during the reaction. The other conditions of 
reaction and isolation of the crosslinked hemoglobins were the same as that of 
oxyhemoglobin. 
With tris(3,5-dibromosalicyl) (3,5-dicarboxy phenoxy) acetate. The reaction of 
deoxyhemoglobin with tris(3,5-dibromosalicyl) 5-acetate isophthalate ether (DBCPA) 
was performed in 0.01 M MOPS, 1 mM NaCN, pH 7.2, essentially according to 
the method of Kluger et al. [77-78]. The concentration of hemoglobin tetramer was 
0.55 mM and the molar ratio of hemoglobin to the reagent was 1 to 1.1. 
The oxyhemoglobin solution was purged with a wet stream of nitrogen gas for 
at least 3 h in an ice bath until the solution was purplish. Then the solution was 
transferred in a water bath already equilibrated at 37 °C. DBCPA, suspended in the 
buffer of 0.01 M MOPS, 1 mM NaCN, pH 7.2, was injected into the 
deoxyhemoglobin solution while purging with nitrogen. The nitrogen purging was 
maintained during the reaction which lasted for 3 hat 37 °C. The reaction solution 
was submerged in an ice bath for 30 min to terminate the reaction. The hemoglobin 
solution was dialyzed against 0.05 M Tris, 1 mM NaCN, pH 8.5, to remove small 
molecules and isolated through a DEAE-Sephadex A-50 column with a linear 
gradient of 0.05 M Tris, 1 mM NaCN, pH 8.5 to 7.2. 
With the elongated bi-linkers and tetra-linkers. The reaction of oxyhemoglobin 
with the bi-linkers and tetra-linkers was performed in 0.01 M MOPS, 1 mM NaCN 
and pH 7 .2. The concentration of hemoglobin was 3.5-5 mM and the molar ratio of 
hemoglobin tetramer to the reagent was 2-2 to 1. The reaction of oxyhemoglobin 
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was done by adding the calculated amount of one of the bi-linkers and tetra-linkers 
to the hemoglobin solution. The mixture was gently swirled every 30 min for a total 
of 3 h at 37 °C. The reaction solution was submerged in an ice bath for 30 min to 
terminate the reaction. The hemoglobin solution was dialyzed in Tris buffer (pH 8.5) 
to remove small molecules and tested by SOS-PAGE. 
With bis(3,5-dibromosalicyl) fumarate in crystallization solutions. Bis(3,5-
dibromosalicyl) fumarate (DBSF) was synthesized according to the method of Zaugg 
et al. [67]. The reaction of oxyhemoglobin with DBSF was done in several 
crystallization solutions at room temperature for 2 days. The solutions were 
prepared according the crystallization conditions of Silva et al. [90] with both high salt 
and low salt conditions. The concentration of hemoglobin was at 1 % and the molar 
ratio of hemoglobin to DBSF was 1 to 1.1. After reaction, the hemoglobin solutions 
were dialyzed against deionized water to remove small molecules. 
In crystal fonns. The calculated amount of tris(3,5-dibromosalicyl) tricarballylate 
(DBSTC) was suspended in the high salt solution of crystallization condition. In a 
glove bag filled with nitrogen gas, crystals from high salt condition were transferred 
into the solution in which DBSTC was added. The molar ratio of the reagent to 
hemoglobin was 1.5 to 1. The sample was stored in a nitrogen-filled desiccator 
sealed with a ground and greased lid at room temperature. After a week, the crystals 
were dissolved in a small amount of deionized water. The hemoglobin solution was 
dialyzed against deionized water to take off small molecules. Crystals from low salt 
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condition were treated in the same way except that DBSTC was suspended in low 
salt solution. 
Bis(3,5-dibromosalicyl) fumarate was used to react with crystal hemoglobin in 
the same conditions as DBSTC in both high salt and low salt solutions. 
Oxygen-binding of hemoglobin 
Oxygen-binding experiments were performed at 37 °C and 1 O psi gas outlet 
for both air and nitrogen on the Hemox-analyzer with an automate plotter for 
recording oxygen equilibrium curves (TCS Products). A blank-run with water was 
made to determine if the membrane of the electrode of oxygen pressure was in 
proper condition in which the minimum reading was between 2.0 and 3.0 mmHg. A 
sample was prepared with 4 ml of Hemox-solution (0.05 M potassium phosphate, 
135 mM NaCl, pH 7.4), 10 µL anti-foaming agent (Sigma) and a calculated volume 
of hemoglobin which produce a final concentration higher than 55 µM per heme. 
The sample was oxygenated with air until equilibrium was reached and the 
potentiometer was adjusted to a meter reading of 150 mmHg, which is the oxygen 
partial pressure under atmospheric conditions. Then the flow of nitrogen was started 
and the deoxygenation was continued until the oxygen partial pressure (p02) 
reading went below 3 mmHg. Finally, the association curve was recorded while the 
sample was oxygenated again. 
P50, a value that describes oxygen affinity, was obtained corresponding to 
the oxygen partial pressure (p02) at 50% of oxygen saturation (Y). The Hill 
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coefficient (n) was obtained by calculation of the slope of log( YI( 1-Y)) as a function of 
1og(p02) near log(Y/(1-Y)) = 0 [7-8, 10]. 
Autoxidation and denaturation of hemoglobin 
The autoxidation and denaturation experiments were conducted using an HP 
8452A UVNIS spectrophotometer, temperature control system and PC computer 
using a program written in QUICK BASIC version 4.5 with QB LIBRARY revision 
2.01 (see Appendices IV and V). 
For the autoxidation experiments, the method of Winterbourn [85] was 
followed. The hemoglobins were freshly purified within a few days of use and the 
samples were dialyzed in 0.01 M MOPS, pH 7.0 (CN- free). Seven cuvettes were 
used, the first one for the reference and the other six for samples. The concentration 
of the sample in each cuvette was adjusted to approximately 14 mM per heme, 
corresponding to an absorbance of 2 at 416 nm. The data were recorded every 30 
min for each sample at 560, 576, 630 and 700 nm for the total time of 17 h. 
There are two common methods to determine the denaturation of 
hemoglobin: (1) measuring the amount of precipitate of hemoglobin as a function of 
time at a particular temperature [91] or (2) determine the unfolding of hemoglobin 
from the absorbance changes as a function of increasing temperature, which was 
developed by White and Olsen [71] and Yang and Olsen [72], and used in this 
dissertation as well. The experiment was performed in 0.01 M MOPS, pH 7.0 (CN-
free), in the presence of 0.9 M guanidine to keep the hemoglobins from precipitating 
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after the samples were denatured. Seven cuvettes were used and the first one was 
for the reference and the other six for the samples of three native hemoglobin and 
three crosslinked hemoglobin. A concentration of 7.0 mM per heme for each 
sample was adjusted, corresponding to an absorbance of 1.0 at 416 nm. Before 
the denaturation experiment, the oxyhemoglobin was converted into 
methemoglobin by oxidizing it with 9.7 x 10 µM potassium ferricyanide for 15 min. 
The program was set up to measure each sample at an interval of about 122 sec at 
280, 406, 410, 418, 542, 576 and 630 nm for a total time of 210 min. 
The other experiments 
Nuclear magnetic resonance (NMR). The 1H and 13C NMR spectra were recorded 
in deuterated solvents (DMSO-d6 or CDCl3) in 5 mm diameter tubes. For the 1H 
NMR spectra, the frequency was 300 MHz, the nucleus was set at 1.250 with a 
spectral width of 4000 Hz, the acquisition time was 3. 752 sec, the pulse width was 
20 msec, the delay time was 0, and the number of transients was 16. For the 13C 
spectra, the frequency was 75 MHz, the nucleus was set at 13,500 with a spectral 
width of 16501.7 Hz, the acquisition time was 1,639 sec, the pulse width was 8.7 
msec, no delay time, and the transient number was 1024. 
Fourier transient infrared (FTIR). The samples were loaded on KBr plates and 
scanned from 4000 to 500 cm-1. The background noise was measured and 
deducted from the sample results. The scan number was 20. 
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Alkaline Agarose Gel Electrophoresis. It was carried out by using commercially 
available alkaline hemoglobin gel (Corning Medical) at 240 volts for 20 min in an 
alkaline hemoglobin buffer (16.7 g of sodium barbital and 2.5 g of barbital in 2 L of 
deionized water, pH 8.6). The gel was stained with the stain solution (1.7 g Amino 
Black 1 OB in 1 L of 5% acetic acid) for 1 O min, immersed in the first 5% acetic acid 
solution for 30 sec, dried in an oven at 65 °C, cooled to room temperature, rinsed in 
the first 5% acetic acid solution for 1 min and in the second 5% acetic acid solution 
until all excess stain was removed, and finally rinsed with deionized water for 2 min 
and dried in a heating oven. 
Sodium dodecylsulfate polyacrylamide Electrophoresis (SOS-PAGE). The 
samples were denatured for 15 min at 100 °C with a denaturing solution (0.25 M Tris 
(pH 6.8), 4% SOS, 20% glycerol, 10% ~-mercaptoethanol, 0.05% bromophenol 
blue). The separation of the samples was carried out using a PHAST system 
(Pharmacia) at a constant current of 10 mA (250 V) and the development was done 
by staining with 0.1 % of PhastGel blue R solution and destaining with a solution 
(30% methanol, 10% of acetic acid and 60% deionized water). The resulting SOS 
gel was scanned on the ISCO gel scanner and the percentage of crosslinking can 
be calculated by using the gel scanning program ISCO. 
Chapter 3 
TERT-BUTYL PROTECTED SALICYLATES AND ELONGATED Bl-LINKERS 
RESULTS 
The first section of this chapter summarizes the analytical results for each of 
the compounds synthesized. The spectra are given at the end of the chapter. 
Tett-butyl salicylate 
1H NMR (DMSO-d6) (see Figure 2 (a)): 3 (ppm) 10.76 {s, 1H, OH), 7.73 (d, 1H, 
ArH), 7.50 (t, 1 H, ArH), 6.93 (m, 2H, ArH), 1.57 (s, 9H, tBu). 
13C NMR (DMSO-d6) (see Figure 2 (b)): 3 (ppm) 168.87 (s, 1C, C=O), 160.50 (s, 
1C, 0-ArC), 135.48 (s, 1C, ArC), 130.05 (s, 1C, ArC), 119.24 (s, 1C, ArC), 117.29 
(s, 1C, ArC), 113.72 (s, 1C, ArC), 82.78 (s, 1C, 0-C), 27.74 (s, 3C, tBu). 
FTIR (KBr) (see Figure 3): 3145.2 cm-1 (aromatic C-H), 2984.9 cm-1 (-CH3), 
1672.3 cm-1 (C=O). 
Tett-butyl 3,5-dibromosalicylate 
Melting point: 108-109 °C. 
1H NMR (CDCl3) (see Figure 4 (a)): 3 (ppm) 11.71 (s, 1 H, OH), 7.83 (d, 1 H, ArH), 
7.80 (d, 1 H, ArH), 1.61 (s, 9H, tBu). 
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13C NMR (CDCl3) (see Figure 4 (b)): & (ppm) 168.24 (s, 1C, C=O), 157.54 (s, 1C, 
0-ArC), 140.34 (s, 1C, ArC), 131.67 (s, 1C, ArC), 115.91(s,1C, ArC), 112.20 (s, 
1C, ArC), 110.37 (s, 1C, ArC), 84.68 (s, 1C, 0-C), 28.08 (s, 3C, tBu). 
4,4'-(1,3-Propanedioxy) dibenzoic acid 
Decomposition: 200 °C. 
1H NMR (DMSO-d6) (see Figure 5 (a)): & (ppm) 7.87 (d, 4H, ArH), 7.02 (d, 4H, 
ArH), 4.19 (t, 4H, O-CH2), 2.20 (m, 2H, CH2). 
13C NMR (DMSO-d6) (see Figure 5 (b)): & (ppm) 168.98 (s, 2C, C=O), 162.05 (s, 
2C, 0-ArC), 131.37 (s, 4C, ArC), 123.02 (s, 2C, ArC), 114.27 (s, 4C, ArC), 64.49 
(s, 4C, O-CH2), 28.38 (s, 1C, CH2). 
4,4'-(1,3-Propanedioxy) dibenzoyl dichloride 
1H NMR (CDCl3) (see Figure 6 (a)): & (ppm) 8.07 (d, 4H, ArH), 6.99 (d, 4H, ArH), 
4.27 (t, 4H, O-CH2), 2.35 (m, 2H, CH2). 
13C NMR (CDCl3) (see Figure 6 (b)): & (ppm) 167.09 (s, 2C, C=O), 164.44 (s, 2C, 
0-ArC), 134.01 (s, 4C, ArC), 125.67 (s, 2C, ArC), 114.62 (s, 4C, ArC), 64.52 (s, 
4C, O-CH2), 28.81 (s, 1C, CH2). 
Bis(terl-butyl 3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) dibenzoate 
Melting point: 81-85 °C. 
1H NMR (CDCl3) (see Figure 7 (a)): & (ppm) 8.18 (d, 4H, ArH), 7.98 (d, 2H, ArH), 
7.89 (d, 2H, ArH), 7.01 (d, 4H, ArH), 4.27 (t, 4H, O-CH2), 2.35 (m, 2H, CH2), 1.35 
(s, 18H, tBu). 
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13C NMR (CDCl3) (see Figure 7 (b)): o (ppm) 163.69 (s, 2C, C=O), 163.42 (s, 2C, 
C=O), 162.63 (s, 2C, 0-ArC), 147.00 (s, 2C, 0-ArC), 138.86 (s, 2C, ArC), 133.75 
(s, 2C, ArC), 133.00 (s, 4H, ArC), 129.83 (s, 2C, ArC), 121.57 (s, 2C, ArC), 119.66 
(s, 2C, ArC), 119.39 (s, 2C, ArC), 114.75 (s, 4C, ArC), 83.31 (s, 2C, 0-C), 64.81 
(s, 2C, O-CH2), 29.33 (s, 1C, CH2), 28.17 (s, 6C, tBu). 
Bis{3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) dibenzoate 
Melting point: 135-140 °C. 
1H NMR (DMSO-d6) (see Figure 8 (a)): o (ppm) 8.29 (s, 2H, ArH), 8.09 (s, 2H, 
ArH), 8.06 (s, 4H, ArH), 7.16 (d, 4H, ArH), 4.29 (t, 4H, O-CH2), 2.26 (m, 2H, CH2). 
13C NMR (DMSO-d6) (see Figure 8 (b)): o (ppm) 163.61 (s, 2C, C=O), 163.23 (s, 
2C, C=O), 162.88 (s, 2C, 0-ArC), 146.89 (s, 2C, 0-ArC), 138.65 (s, 2C, ArC), 
133.19 (s, 2C, ArC), 132.32 (s, 4C, ArC), 128.20 (s, 2C, ArC), 120.31 (s, 2C, ArC), 
119.53 (s, 2C, ArC), 118.84 (s, 2C, ArC), 64.80 (s, 2C, O-CH2), 28.10 (s, 1 C, CH2). 
4,4' -Triethyleneglycol dibenzoic acid ether 
Decomposition: 300 °c. 
1H NMR (CDCl3) (see Figure 9 (a)): o (ppm) 7.88 (d, 4H, ArH), 7.01 (d, 4H, ArH), 
4.14 (t, 4H, O-CH2), 3.75 (t, 4H, O-CH2), 2.49 (s, 4H, O-CH2). 
13C NMR (CDCl3) (see Figure 9 (b)): o (ppm) 167.00 (s, 2C, C=O), 162.09 (s, 2C, 
0-ArC), 131.35 (s, 4C, ArC), 123.02 (s, 2C, ArC), 111.28 (s, 4C, ArC), 69.96 (s, 
2C, O-CH2), 68.81 (s, 2C, O-CH2), 67.43 (s, 2C, O-CH2). 
4,4'-Triethyleneglycol diisophthalyl ether dichloride 
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1H NMR (DMSO-d6) (see Figure 10 (a)): 8 (ppm) 8.05 (d, 4H, ArH), 6.96 (d, 4H, 
ArH), 4.20 (t, 4H, 0-CHi), 3.89(t, 4H, O-CH2), 3,74{s, 4H, O-CH2). 
13C NMR (DMSO-d6) (see Figure 10 (b)): 8 (ppm) 167.09 (s, 2C, C=O), 164.58 (s, 
2C, 0-ArC), 133.96 (s, 4C, ArC), 125.62 (s, 2C, ArC), 114.76 (s, 4C, ArC), 70.95 
(s, 2C, O-CH2), 69.47 (s, 2C, O-CH2), 67.92 (s, 2C, O-CH2). 
Bis( tett-butyl 3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether 
Melting point: 115-130 °C. 
1H NMR (DMSO-d6) (see Figure 11 (a)): 8 (ppm) 8.16 (d, 4H, ArH), 7.99 {d, 2H, 
ArH), 7.90 (d, 2H, ArH), 7.01 (d, 4H, ArH), 4.23 (t, 4H, O-CH2), 3.91 (t, 4H, O-
CH2), 3.78 (s, 4H, O-CH2), 1.35 (s, 18H, CH3). 
13C NMR (DMSO-d6) (see Figure 11 (b)): 8 (ppm) 163.41 (s, 2C, C=O), 163.12 (s, 
2C, C=O), 162.35 {s, 2C, 0-ArC), 146.64 (s, 2C, 0-ArC), 138.53 (s, 2C, ArC), 
133.44 {s, 2C, ArC), 132.61{s,4C, ArC), 129.51(s,2C, ArC), 121.21 (s, 2C, ArC), 
119.34 {s, 2C, ArC), 119.06 {s, 2C, ArC), 114.55 {s, 4C, ArC), 83.02 (s, 2C, 0-C), 
70.94 (s, 2C, O-CH2), 69.59 {s, 2C, O-CH2), 67.69 {s, 2C, O-CH2), 27.83 (s, 6C, 
Bis(3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether 
Melting point: 157-161 °C. 
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1H NMR (CDCl3) (see Figure 12 (a)): 8 (ppm) 8.28 (d, 2H, ArH), 8.08 (s, 2H, 
ArH), 8.05 (d, 4H, ArH), 7.14 (d, 4H, ArH), 4.22 (t, 4H, O-CH2), 3.78 (t, 4H, O-
CH2), 3.63 (s, 4H, O-CH2). 
13C NMR (CDCl3) (see Figure 12 (b)): 8 (ppm) 163.59 (s, 2C, ArC=O), 163.25 (s, 
2C, ArC=O), 162.86 (s, 2C, 0-ArC), 146.87 (s, 2C, 0-ArC), 138.63 (s, 2C, 
ArC), 133.17 (s, 2C, ArC), 132.26 (s, 4C, ArC), 128.16 (s, 2C, ArC), 120.25 (s, 
2C, ArH), 119.51 (s, 2C, ArC), 118.62 (s, 2C, ArC), 114.85 (s, 4C, ArC), 69.94 
(s, 2C, O-CH2), 68.71 (s, 2C, O-CH2), 67.69 (s, 2C, O-CH2). 
Crosslinking reaction 
DBPDB crosslinked hemoglobin gave 5% dimers, and DBEBE crosslinked 
hemoglobin, 35% dimers in SOS-PAGE analysis (Table 3). 
DISCUSSION 
Teri-butyl protection of 3,5-dibromosalicylic acid. Teri-butyl 3,5-
dibromosalicylate was used to prepare aspirin crosslinking reagents with 
unreactive acid chlorides in previous work [78, 81, 92]. In this study, tert-butyl 
3,5-dibromosalicylate was synthesized by coupling 3,5-dibromosalicylic acid with 
tert-butyl alcohol in the present of DCC as a coupling reagent (Scheme X). To 
minimize the self-reaction of carboxyl group with phenol hydroxyl of the salicylic 
acid, a large amount of tert-butyl alcohol was used in the reaction as solvent 
and reactant. The desired product is white needle crystals with a melting point of 
Table 3. SOS-PAGE analysis of crosslinked hemoglobins by the elongated 
bi-linkers. 
Hb sample % Monomer % Dimer 
DBPDB-XL 95 5 
DBEBE-XL 65 35 
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108-109 °C after recrystallization from ethanol. It is stable in alkaline media but 
hydrolyzed in strong acidic media. 
Tert-butyl salicylate was characterized by 1H and 13C NMR (Figure 2): the 
resonance at chemical shift cS 10.76 ppm is due to the hydroxyl Hydrogen, the four 
Teri-butyl 3,5-
dibromosalicylate 
peaks between cS 7.75 - 6.89 are due to the aryl 
hydrogens and the nine peaks at cS 1.57 are due to 
the methyl groups; the peak at cS 168.87 is due to 
the carbonyl carbon, the six peaks at cS 160.50 -
113.72 are due to the aryl carbons, the peak at cS 
82. 78 is due to the methine carbon and the peak 
at cS 27.74 is due to the methyl's carbons. Tert-butyl 3,5-clibromosalicylate was 
characterized by 1H and 13C NMR (Figure 4): the peak at cS 11.71 is due to the 
hydroxyl hydrogen, the two resonances at cS 7.83 and 7.80 are due to the aryl 
hydrogens and the peak at cS 1.61 is due to the methyl groups; the peak at cS 168.24 
is due to the carbonyl carbon, the six peaks at cS 157.54 - 110.37 are due to the aryl 
carbons, the peak at cS 84.68 is due to the methine carbon and the peak at cS 28.08 
is due to the methyl carbon. The tert-butyl protection of the salicylic acids was 
successful. 
To elongate the bridging lengths of crosslinkers, amide-containing chains 
of different lengths were first considered as bridging structures at the first design 
65 
because of its hydrophilic character. However, the amide bond reacts with 
thionyl chloride and is cleaved during the preparation of the acid chloride: 
RNHCOR' + SOCl2 ~ RCI + R'CN + 802 + HCI 
We found that ether linkages were very stable to refluxing with thionyl chloride. 
The introduction of hydrophilic multi-ethyleneglycol into the crosslinkers can 
improve the solubility in aqueous solution. This is important because the 
hydrophilic bridging structure prevents its folding in aqueous solution which 
makes its bridging size much smaller than expected. The acid chloride 
compounds were prepared by reflux with thionyl chloride in the presence of 
DMF. The bis{3,5-dibromosalicyl) esters were synthesized successfully 
according to the method developed by Klotz et al. [81]. The bridging lengths of 
the reagents were determined by computer modeling and are summarized in 
Table 4. 
The bis(3,5-dibromosalicyl) linkers, DBPDB and DBEBE, were designed 
to crosslink between two intramolecular tetrameric hemoglobins as shown in 
Scheme XI. In the first step, deoxyhemoglobin is crosslinked with bis(3,5-
dibromosalicyl) fumarate (DBSF) between Lys99's of the a chains [70]. In the 
second step, the two intramolecularly crosslinked hemoglobins would be 
crosslinked intermolecularly between Lys82J3 in different tetramers to form an 
octameric hemoglobin. 
The syntheses of bis(3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) dibenzoate 
and bis(3,5-dibromosalicyl) 4,4'-triethyleneglycol diisophthalate ether failed when the 
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Table 4. Bridging lengths between carbonyl carbons of the crosslinkers. 
Compound Bridging length (A) 
DBPDB 14.3 
DBEBE 19.6 
Scheme XI 
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dibenzoyl chlorides did not react with 3,5-dibromosalicylic acid in the present of 
triethylamine. The crosslinkers were synthesized in this dissertation in four main 
steps. (1) The production of dibenzoic acids in a Williamson ether synthesis. (2) The 
production of the corresponding acid chlorides with thionyl chloride using DMF 
catalysis. (3) The production of the corresponding bis(tert-butyl 3.5-
dibromosalicylate) dibenzoate esters. And (4) the deprotection of tert-butyl esters 
by triflouroacetic acid to form the corresponding bis(3,5-dibromosalicyl) dibenzoate 
ester. 
Bis(3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) dibenzoate (DBPDB) was 
characterized by 1H and 13C NMR (Figure 8): The resonances at 8 8.29 and 8.09 
are due to the four aryl hydrogens (outer rings), the resonances at 8 8.06 and 7.16 
are due to the eight aryl hydrogens (inner rings) and the peaks at 8 4.29 and 2.26 
are due to the six methylene hydrogens; the two peaks at 8 163.61 and 163.23 are 
due to the carbonyl carbons on the aspirin and benzoate aromatic rings, the ten 
peaks at 8 162.88 - 114.67 are due to the aspirin and benzoate aryl carbons and the 
two peaks at 8 64.80 and 28.10 are due to the methylene carbons. 
0 0 
I I 
COH HOC 
••--Q-o-tO-o-cH,cH,cH,-o-QJ-P•• 
Br Br 
Bis(3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) dibenzoate 
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Bis(3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether was 
characterized by 1H and 13C NMR (see Figure 12): The resonances at o 8.28 and 
8.08 are due to the four aryl hydrogens (outer rings), the resonances at o 8.05 and 
7.14 are due to the eight aryl hydrogens (inner rings), and the resonances at o 4.22, 
3.78 and 3.63 are due to the twelve methylene hydrogens; the two peaks at o 
163.59 and 163.25 are due to the carbonyl carbons on the aspirin and benzoate 
benzenes, the ten peaks at o 162.86 - 114.85 are due to the aspirin and benzoate 
benzene carbons and the three peaks at o 69.94, 68.71 and 67.69 are due to the 
methylene carbons. The syntheses of the two aspirin double linkers were 
successful. 
0 0 
~OH HO~ 
B•-QO-t.oO..cH,CH,OCH,CH,OCH,CH,-o....Q-L°:P-B• 
Bis{3,5-dibromosalicyl) 4,4'-triethyleneglycol dibenzoate ether 
Reaction of hemoglobin with DBPDB had much fewer dimers shown in 
SOS-PAGE analysis than with DBEBE (Table 3). For DBEBE crosslinked 
proteins, 35% dimers by SOS-PAGE infers that there was intramolecular rather 
than intermolecular crosslinking since the intermolecular reaction should give 
only 25% dimers. No octamer was isolated from DBEBE crosslinked proteins by 
G-150 (Fine) gel filtration. The DBEBE crosslinking of hemoglobin must be 
between two subunits of the same molecule (Figure 13 (A)) and some 
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crosslinking at the same subunit (Figure 13 (B)). The cleft between the two ~ 
chains is too small for the elongated bi-linkers to enter and react with the 
Lys82's. Moreover, the mono ester group at each end of the bi-linkers may not 
be as sterospecific as DBSF and may react with other amino groups on the 
surface of hemoglobin. The other end of the bi-linkers with a mono ester group 
may bend backward to the same hemoglobin and react with an amino group at 
the same or different subunit. DBPDB, due to its relatively short structure, 
mainly crosslinked within the same subunit (Figure 13 (B)). 
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Figure 2. 1H and 13C NMR of terl-butyl salicylate (DMSO-d6). 
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1.e 
!i~: 
·,;-
-fll' JV 
... ... 
'" "' '-:;-;-' ........... 
- ;,t 
,,. !.'!':h .••• 
! 
'rf 't' ) 
.tLl 
.. .. 
-
... •.. ~.1. ... 
(b) 13C NMR. 
• !: 
;j 
' ;1 I 
i ' 'I 
I I ! 1 ! I 
.JJ,; ii l I I ,JI!. p Ji 
• JO JO .:c JO 
lfl I 
~~··' ,.,.,.. 
'{ qi 1 • 
r· ll_ 
1 ..... 
"-;:":'""'"" 
E 
I 
I 
I 
I 
I 
I 
u d 
JO It 
L! 
,, It 
I 
~ 
... 
:;1' .· : 
') i 
l I .. " It'..:>' I .. I j 
72 
73 
Figure 3. FTIR of terl-butyl salicylate (KBr). 
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Figure 4. 1H and 13C NMR of tett-butyl 3,5-dibromosalicylate (CDCl3). 
(a) 1H NMR. 
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Figure 5. 1H and 13C NMR of 4,4'-(1,3-propanedioxy) dibenzoic acid 
(DMSO-d6). 
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(a} 1H NMR. 
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Figure 6. 1H and 13C NMR of 4,4'-(1,3-propanedioxy) dibenzoyl dichloride 
(CDCl3). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 7. 1H and 13C NMR of bis(terl-butyl 3,5-dibromosalicyl) 4,4'-(1,3-
propanedioxy) dibenzoate (CDCl3). 
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(a) 1H NMR. 
(b) nc NMR. 
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Figure 8. 1H and 13C NMR of bis(3,5-dibromosalicyl) 4,4'-(1,3-propanedioxy) 
dibenzoate (DMSO-d6). 
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(a) 1H NMR. 
(b) 1ic NMR. 
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Figure 9. 1H and 13C NMR of 4,4'-triethyleneglycol dibenzoyl acid ether 
(DMSO-d6). 
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Figure 10. 1H and 13C NMR of 4,4'-triethyleneglycol dibenzoyl ether dichloride 
(CDCl3). 
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Figure 11. 1H and 13C NMR of bis(tett-butyl 3,5-dibromosalicyl) 4,4'-
triethyleneglycol dibenzoate ether (CDCl3). 
89 
(a) 1H NMR. 
(b) 13C NMR. 
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Figure 12. 1H and 13C NMR of bis(3,5-dibromosalicyl) 4,4'-triethyleneglycol 
dibenzoate ether (DMSO-d6). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 13. Possible intra and inter-subunit crosslinking of hemoglobin 
with the elongate bi-linkers. 
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Chapter 4 
TRIS{3,5-DIBROMOSALICYL) TRICARBALL YLA TE 
AND CROSSLINKING OF HEMOGLOBIN WITH THE TRILINKER 
RESULTS 
The first section of this chapter summarizes the analytical results for each of 
the compounds synthesized. The spectra are given at the end of the chapter. 
Tricarballylic 1-acid chloride 2,3-anhydride 
1H NMR (DMSO-d6) (see Figure 14 (a)): 8 (ppm) 3.52-3.48 (m, 2H, CH2-C=O), 
3.46-3.39 (m, 1 H, CH-C=O), 3.30-2.77 (m, 2H, CH2-C=O). 
13C NMR (DMSO-d6) (see Figure 14 (b)): 8 (ppm) 172.30 (s, 1C, C=O), 171.35 (s, 
1C, C=O), 168.11 (s, 1C, C=O), 46.11 (s, 1C, C*-C=O), 37.20 (s, 1C, C*-C=O), 
33.40 (s, 1 C, C*-C=O). 
Tricarballylyl trichloride 
Boiling point: 117-119 °C at 4.2-4.3 mmHg. 
1H NMR (CDCl3,) (see Figure 15 (a)): 8 3.65-3.57(m, 1H, CH-C=O), 3.56-3.28 (m, 
4H, CHrC=O). 
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13C NMR (CDCl3) (see Figure 15 (b)): 8(ppm)172.34 (s, 1C, C=O), 171.51 (s, 2C, 
C=O), 48.37 (s, 1C, C*H-C=O), 46.34 (s, 2C, C*H2-C=O). 
FTIR (KBr) (see Figure 16): 2934.0 (d), 1788.1 (s), 970.9 (m) cm-1• 
Tris(terl-butyl 3,5-dibromosalicyl) tricarballylate 
Melting point: 66-70 °C. 
1H NMR (CDCl3) (see Figure 17 (a)): 8 (ppm) 7.94-7.81 (m, 6H, ArH), 3.95 (m, 
1 H, CH-C=O), 3.61-3.22 (m, 4H, CHrC=O), 1.56 (d, 27H, tBu). 
13C NMR (CDCl3) (see Figure 17 (b)): 8 (ppm) 169.51-168.38 (s, 3C, C=O), 
161.44 (s, 3C, C=O), 146.91 (d, 3C, 0-ArC), 138.74 (d, 3C, ArC), 133.12 {d, 3C, 
ArC), 128,26 (d, 3C, ArC), 119.42 (d, 3C, ArC), 119.15 (d, 3C, ArC), 83.04 (d, 
3C, 0-C), 36.92 (s, 1 C, C*H-C=O), 34.60 (s, 2C, C*HrC=O), 28.01 (s, 9C, tBu). 
Tris(3,5-dibromosalicyl) tricarballylate 
Melting point: 147-151 °c. 
1H NMR (DMSO-d6) (see Figure 18 (a)): 8 (ppm) 8.26 (m, 3H, ArH), 8.04 (m, 3H, 
ArH), 3.73 (m, 1H, CH-C=O), 3.45-3.10 (m, 4H, CH2-C=O). 
13C NMR (DMSO-d6) (see Figure 18 (b)): 8 (ppm) 169.16-168.30 (s, 3C, C=O), 
163.50 (d, 3C, As-C=O), 146.50 (d, 3C, 0-ArC), 138.89 (d, 3C, ArC), 133.27 (d, 
3C, ArC), 127.48 (d, 3C, ArC), 119.16 (d, 3C, ArC), 119.07 (d, 3C, ArC), 36.39 
(s, 1 C, C*H-C=O), 34.10 (s, 2C, C*H2-C=O). 
Isolation of the crosslinked proteins 
97 
Using ion-exchange chromatography, three components were isolated 
from the reaction of oxyhemoglobin (Figure 19) and four components from the 
reaction of deoxyhemoglobin (Figure 20) with tris(3,5-dibromosalicyl) 
tricarballylate. SOS-PAGE exhibited that the first peaks of both oxy and deoxy 
reactions were uncrosslinked hemoglobin and the other peaks were bi-
crosslinked hemoglobins (Table 5); the second peaks were the major products 
from both oxy and deoxy reactions. 
Denaturation 
The effect of the tricarballylate crosslink on the thermal stability of 
hemoglobin was remarkable as shown in Figure 21. Native hemoglobin and the 
components from the second peaks of both oxy and deoxy reactions were 
tested. The denaturation transition (Tm) of native hemoglobin is 41.0°C and 
those of the oxy and deoxy crosslinked proteins 55.5 °C and 54.0 °C, increasing 
14.5 and 13.0°C, respectively. 
Autoxidation 
Autoxidation of native hemoglobin and the components from the second 
peaks of oxy and deoxy reactions were tested (see Figure 22). The deoxy 
crosslinked protein (kapp = 8. 70 x 10-2 ± 4.15 x 1 o-7) was found to be more 
susceptible to autoxidation than native protein (kapp = 6.49 x 10-2 ± 2.32 x 1 o-7). 
The autoxidation rate of the oxy crosslinked protein (kapp = 6.89 x 10-2 ± 2. 75 x 
10-7) however, remained unchanged after crosslinking, as we desired. 
Oxygen-binding 
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Table 5. SOS-PAGE Results for Isolated Crosslinked Hemoglobins. 
Sample % Monomer % Dimer 
HbA 100 0 
OxyXL-HbA 
Peak 1 100 0 
Peak2 50 50 
Peak3 56 44 
Deoxy XL-Hb A 
Peak 1 100 0 
Peak2 50 50 
Peak 3 59 41 
Peak4 57 43 
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Figure 23 shows the oxygenation curves of fresh blood (P50 = 20.2 
mmHg, n = 2.8), native hemoglobin (P50 = 11.7 mmHg, n = 2.0) and the 
components of the second peaks from the oxy (P50 = 3.6 mmHg, n = 1.2) and 
deoxy (P50 = 7.7 mmHg, n = 1.2) crosslinking. Obviously, in both oxy and deoxy 
crosslinking reactions the oxygen affinity of the hemoglobins increased and the 
Hill coefficient decreased. 
The relevant data of denaturation, autoxidation and oxygen-binding are 
summarized in Table 6. 
DISCUSSION 
The synthesis of tris(3,5-
dibromosalicyl) triscarballylate used the 
method of Bucci et al. [92) but the 
0 
0 
D 
HOC:qBr 
I H O 
~ I Br 
production of tricarballylyl trichloride 
-Q-coH ott-J-A..-o Br 0-C-CH 
differred. Instead of phosphorus 
pentachloride (PCl5), we used SOCl2 with 
DMF catalysis to obtain the acid chloride. 
However, formation of the acid chloride is 
I Br 
H-c-c ... :Q Br I I 0 H 0 
HOC Br 
I 
0 
Tris(3,5-dibromosalicyl) 
tricarballylate 
dependent on the amount of DMF. Tricarballylic 1-acid chloride 2,3-anhydride 
(crystals) (Figure 14) or tricarballylyl trichloride (liquid) (Figure 15) was obtained 
if less or a greater amount of DMF was applied, respectively. The desired 
trilinker was characterized by 1H and 13C NMR spectroscopy (Figure 18): the six 
Table 6. Comparison of Functional Properties of Crosslinked 
Hemoglobins. 
Sample Tm (oC) kappx100 (h"1) f112 (h) P50 
Fresh RBC NA NA NA 20.2 
HbA 41.0 6.49±2.32x 10·5 10.7 11.7 
Deoxy-XL-Hb A 54.0 8.70±4.15x10-5 7.97 7.7 
Oxy-XL-Hb A 55.5 6.89±2. 75x 10-5 10.06 3.6 
100 
n 
2.8 
2.0 
1.2 
1.2 
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hydrogen resonances at chemical shift 8 8.26 and 8.04 ppm are due to the three 
aspirin's aryl hydrogens, the one resonance at 8 3. 73 is due to the methine, and 
because of the stereo structure, two hydrogen resonances, one due to each of 
the two methylenes are at 8 3.45-3.38 and the other two are at 8 3.18-3.1 O; the 
two peaks at 8 169.16 and 168.30 are assigned to the tricarballylate carbonyl 
carbons; a peak at 8 163.50, to the carbonyl carbons on the aspirin aromatic 
rings; six peaks at 8 146.49 - 119.07, to the carbons of aspirin aromatic rings; a 
peak at 8 36.39, to the methine carbon and a peak at 8 34.10, to the methylene 
carbons. The synthesis of the reagent was successful. 
The isolations of the DBSTC crosslinked derivatives (Figures 19 a and 20 
a) show only one major product corresponding to the bi-linked species from both 
oxy and deoxyhemoglobin reactions. It is likely that the third 3,5-dibromosalicyl 
ester group is hydrolyzed and does not react with another hemoglobin residue. 
This type of reaction has been observed previously with tris(3,5-dibromosalicyl) 
trimesate [78]. SOS-PAGE gels showed the expected 1 :1 ratio of dimers to 
monomers for a protein with a single inter-subunit crosslink (Figures 19 b and 
20 band Table 5). The intramolecular crosslink improved the thermal stability. 
According to the previous work [69, 78), the most likely possibility of the 
crosslinking of hemoglobin by the tri-linker was at the specific site between 
LysJ3182 and LysJ3282, which is consistant with these results. The crosslinking of 
intra-hemoglobin covalently between two J3 chains apparently improved the 
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thermal stability (Figure 21 and Table 6). The crosslinking of both oxy and 
deoxyhemoglobin increased the Tm by 14.5 and 13.0 °C (Figure 4), respectively. 
The increase in Tm was identical to that observed to similar length crosslinks 
between Lys82131 and Lys82132 [71-73). 
The autoxidation of hemoglobin is a pseudo first-order reaction within 17 h 
(Figure 22). The faster rate of autoxidation of the deoxy crosslinked hemoglobin 
than those of native hemoglobin and the oxy crosslinked hemoglobin (Figure 22 
and Table 6) resulted from the different quaternary structures after crosslinking. 
Deoxyhemoglobin (T state) autoxidizes faster than oxyhemoglobin (R state) [26, 
94). Yang and Olsen [95] showed that the apparent autoxidation rate of 
fumarate-crosslinked hemoglobins increased 78% for the a99 Lys crosslinked 
species that favors the T state conformation but only 22% for the 1382 Lys 
crosslinked protein that prefers the R state. The 34% increase observed here for 
the tricarballylate crosslinked hemoglobin is similar to the earlier results for the 
1382 Lys fumarate-crosslinked hemoglobin. The two 13-chains are closer in the R 
state than in the T state [96-97). Thus, the Lys 1382's are closer in 
oxyhemoglobin than in deoxyhemoglobin. The size of DBSTC prevents it from 
entering the cavity between the a-chains. Therefore, the most probable site for 
crosslinking by this reagent is between the two Lys 1382's under either oxy or 
deoxy reactions. Due to the length of the reagent, both oxy and deoxy reaction 
products would favor the R state quaternary structure. The slight decrease in 
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oxygen affinity of the product produced under deoxy conditions corresponds to 
an increase in autoxidation rate. This effect is more dramatic in some other 
crosslinked hemoglobins, such as the a99 fumarate crosslinked species [95]. 
However, results from some crosslinked hemoglobins are difficult to give a 
reasonable explanation using conformation theory. Generally, crosslinking of 
hemoglobin at the BPG binding-site effects the autoxidation rate less than at 
some where else. This will be discussed more in Chapter 5. 
It was known that in the oxy state the two 13 chains were closer to each 
other than those in deoxy state [96-97], and therefore the Lysj382's in the R state 
would be closer to each other than those in the T state. 
Although the Hill coefficient n decreased due to DBSTC crosslinking, the 
n values of the crosslinked proteins are still above 1.0, that is the oxygen binding 
remains slightly cooperative. Compared to native hemoglobin, the oxygen 
affinities of oxy crosslinked hemoglobins increased significantly (Figure 23 and 
Table 6) due to the R state conformation of the crosslinked proteins. The oxygen 
affinity of the deoxy crosslinked hemoglobin however, was not as low as we 
expected (Figure 23 and Table 6). The crosslinking of deoxyhemoglobin by the 
short crosslinker would pull the Lysj382's closer, resulting in the conformation to 
shift to R-state in some degree and an increase in the oxygen affinity. The 
distances between the three DBSTC ester carbonyl carbons are different due to 
the asymmetrical structure (Table 7). Therefore, deoxyhemoglobin would favor 
the longer side of DBSTC to crosslink, and oxyhemoglobin, the shorter side. It is 
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Table 7. Distances between DBSTC ester carbonyl carbons. 
Tri-linler Bridging distance (A) 
DBSTC 5.31 5.75 6.19 
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consistant with Kluger's work [77] that oxygen affinity increases with decrease of 
bridging length. 
Figure 14. 1 H and 13C NMR of tricarballylic 1-acid chloride 2,3-anhydride 
(DMSO-d6). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 15. 1H and 13C NMR of tricarballylyl trichloride (CDCl3). 
(a) 1H NMR. 
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(b) 13C NMR. 
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Figure 16. FTIR of tricarballylyl trichloride. 
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Figure 17. 1H and 13C NMR of tris(tert-butyl 3,5-dibromosalicyl) 
tricarballylate (CDCl3). 
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Figure 18. 1H and 13C NMR of tris(3,5-dibromosalicyl) tricarballylate 
(DMSO-d6). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 19. Anion-exchange chromatography and SOS-PAGE of hemoglobin 
crosslinked by DBSTC under oxy conditions. 
(a) Ion-exchange chromatography. 
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Figure 20. Anion-exchange chromatography and SOS-PAGE of 
hemoglobin crosslinked by DBSTC under deoxy conditions. 
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(a) Ion-exchange chromatography. 
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Figure 21. Denaturation of native and DBSTC crosslinked hemoglobins. 
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Figure 22. Autoxidation of native and DBSTC crosslinked hemoglobins. 
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Figure 23. Oxygen dissociation curves of fresh blood, native and DBSTC 
crosslinked hemoglobins. 
\ I •
 I • • \ •
 • ' ' ' 
~ I 
<( 
<( ~ 
CD 
I 
CD 
I 
.
.
.
.J 
Cl 
:i;: S< 
>< 
0 
><! 
0 ~ 
0 _.
 
z 
w
 
CD 
:J 
Cl 
0 
I I 
I 
I 
I 
I I 
I 
~ ,\ 
' 
\
' 
' 
'
' 
,
,
 
' 
""' 
.
.
.
.
.
.
.
.
 
.
_
, 
.
_
, 
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
.
 
' 
"
"
'.. 
.
.
.
_
 
.. 
.. 
.
.
.
.
 
.
.
.
_
 
.. 
-
-
.. 
0 0) 
0 <O 
0 M 
125 
(;) 
t t 01 0 a. 
Chapter 5 
TRIS(3,5-DIBROMOSALICYL) (3,5-DICARBOXY PHENOXY) ACETATE 
AND CROSSLINKING OF HEMOGLOBIN WITH THE TRI-LINKER 
RESULTS 
The first section of this chapter summarizes the analytical results for each of 
the compounds synthesized. The spectra are given at the end of the chapter. 
Computer aided design. Figure 24 shows the reagents at the specific reaction 
site of hemoglobin. The distances of the amino groups (nucleophiles) of the 
three residues (two Lys82ps and one Val1,8) and three aspirin ester carbonyl 
carbons of DBSTC are 2.55, 2.58 and 5.53 A (Figure 24 (A)); DBSTM, 2.47, 
2.50 and 3.95 A (Figure 24 (B)); and DBCPA, 2.48, 2.47 and 2.48 A (Figure 24 
(C)), respectively. 
(3,5-Dicarboxy phenoxy) acetic acid 
Melting point: > 360°C. 
1H NMR (DMSO-d6) (see Figure 25 (a)): o (ppm) 8.04 (m, 1 H, ArH), 7.53 (m, 2H, 
ArH), 4.49 (s, 2H, 0-CHi-C=O). 
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13C NMR (DMSO-da) (see Figure 25 (b)): o (ppm) 170.55 (s, 2C, C=O), 167.41 
(s, 1C, C=O), 158.26 (s, 1C, 0-ArC), 134.37 (s, 2C, ArC*-C=O), 122.30 (s, 1C, 
ArC), 118.36 (s, 2C, ArC), 66.40 (s, 2C, 0-C"'HrC=O). 
(3,5-Dicarboxy phenoxy) acetyl trichloride 
Melting point: 60.5-62°C. 
1H NMR (CDCb) (see Figure 26 (a)): o (ppm) 8.55 (m, 1 H, ArH), 7.87 (m, 2H, 
ArH), 5.09 (s, 2H, 0-CHrC=O). 
13C NMR (CDCb) (see Figure 26 (b)): o (ppm) 169.05 (s, 1C, C=O), 166.77 (s, 
2C, C=O), 157.44 (s, 1C, ArC), 135.81 (s, 1C, ArC), 127.81 (s, 2C, ArC), 
122.82 (s, 2C, ArC), 72.36 (s, 2C, 0-C"'HrC=O). 
Tris(tert-butyl 3, 5-dibromosalicylate) (3,5-dicarboxy phenoxy) acetate 
Melting point: 104-107°C. 
1H NMR (CDCb) (see Figure 27 (a)): o (ppm) 8.76 (m, 1 H, ArH), 8.18 (m, 2H, 
ArH), 8.03 (m, 2H, ArH), 7.98 (m, 1 H, ArH), 7.94 (m, 2H, ArH), 7.88 (m, 1 H, 
ArH), 5.19 (s, 2H, 0-CHrC=O), 1.55 (s, 9H, CH3), 1.39 (s, 18H, CH3). 
13C NMR (CDCb) (see Figure 27 (b)): o (ppm) 165.12 (s, 1 C, C=O), 162.04 (s, 
2C, C=O), 161.63 (s, 2C, C=O), 160.99 (s, 1C, C=O), 157.97-119.09 (16s, 
24C, ArC & ArC), 83.33 (s, 1 C, 0-C), 83.17 (s, 2C, 0-C), 65.29 (s, 2C, 0-
C"'HrC=O), 28.06 (s, 3C, CH3), 27.97 (s, 6C, CH3), 
Tris(3, 5-dibromosalicyl) (3,5-dicarboxy phenoxy) acetate 
Melting point: 150-152°C. 
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1H NMR (OMSO-ds) (see Figure 28 (a)): o (ppm) 8.43 (s, 1 H, ArH), 8.26 (d, 2H, 
ArH), 8.20 (d, 1 H, ArH), 8.06 (s, 4H, ArH), 8.01 (d, 1 H, ArH), 5.39 (s, 2H, 0-
CHrC=O). 
13C NMR (OMSO-ds) (see Figure 28 (b)): o (ppm) 166.16 (s, 1C, C=O), 163.50 
(s, 2C, C=O), 163.47 (s, 1C, C=O), 162.21 (s, 2C, C=O), 158.15-119.18 (16s, 
24H, ArC & ArC), 65.36 (s, 2C, 0-C*HrC=O). 
Isolation of the crosslinked proteins 
Anion-exchange chromatography produced three components from 
reaction of hemoglobin with tris(3,5-dibromosalicyl) (3,5-dicarboxy phenoxy) 
acetate (OBCPA) (Figure 29 a). The yield of crosslinked proteins of the third 
peak was high too. 
Electrophoresis 
The SOS-PAGE showed that the first peak was uncrosslinked hemoglobin 
with only a monomeric band, and the others are crosslinked hemoglobins with 
both monomeric (Mr 16,000) and dimeric (Mr 32,000) bands (Figure 29 b and 
Table 8). SOS-PAGE also showed multiple bands at dimer ranges of both the 
second and third peaks. 
Denaturation 
Figure 30 shows the denaturation of native hemoglobin A and the 
crosslinked hemoglobins. The curves of the slope of the Soret absorbance 
versus temperature have a single broad peak for each. The Tm was determined 
by measuring the temperature corresponding to the minimum of the 
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Table 8. SOS-PAGE Results for Isolated Crosslinked Hemoglobins. 
Sample % Monomer % Dimer 
HbA 100 0 
The 1st peak 100 0 
The 2nd peak 51 49 
The 3rd peak 50 50 
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peak. The Tm of the crosslinked hemoglobins was 55.0 °C for both the second 
and third peaks, 14.0 °C (A Tm) higher than that of native hemoglobin (41.0 °C). 
Autoxidation 
Figure 31 shows the autoxidation of native and the DBCPA crosslinked 
hemoglobins. The hemoglobin concentrations decreased linearly at a pseudo 
first-order rate. The kapp obtained by calculation of the slopes of the regression 
lines showed that the autoxidation of the crosslinked hemoglobins of both the 
second and third peaks remained unchanged at approximately 7.0 x 10-2 h"1 
corresponding to the half-life time 10.0 h, compared with that of native 
hemoglobin. 
Oxygen-binding 
Figure 32 shows oxygen equilibria of native and the DBCPA crosslinked 
hemoglobins. The DBCPA bi-linking of hemoglobin caused a decrease in 
oxygen affinity, raising the P50 value from 11.6 to 15. 9 mmHg. The tri-linked 
proteins had a higher oxygen affinity with P50 0.86 mmHg. Comparing with that 
of native hemoglobin (n = 2.5), the Hill coefficient of the bi-linking of hemoglobin 
remained almost unchanged (n = 2.4), while that of the tri-linking .of hemoglobin 
was half of the pre-crosslinked (n = 1.2). 
The relevant data of denaturation, autoxidation and oxygen-binding were 
summarized in Table 9. 
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Table 9. Comparison of Functional Properties of Crosslinked Hemoglobins. 
Sample Tm (QC) ~Tm (QC) kapp X 100 (h"1} f112 (h) Pso (mm) n 
HbA 41.0 0.0 6.99±3.02 x10-5 9.92 11.6 2.5 
The 2nd peak 55.0 14.0 6.80±3.00x10-5 10.2 15.9 2.4 
The 3rd peak 55.0 14.0 6.99±2.90x10-5 9.92 8.6 1.3 
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DISCUSSION 
The synthesis of tris(3,5-dibromosalicyl) (3,5-dicarboxy phenoxy) acetate 
contains four steps: The first step is production of a (3,5-dicarboxy phenoxy) 
0 
I 
HOC:qBr 
0 0 
I I 
;-(_H o "' -~-o Br 9,~0-~CH,-'\_( B• 
"' i-~ 
HO~ Br 
0 
Tris(3,5-dibromosalicyl) 
(3,5-dicarboxy phenoxy) acetate 
acetic acid; the second step is 
production of the corresponding 
tri(acid chloride); the third step is 
production of the corresponding 
tris( tert-butyl 3, 5-dibromosalicyl) 
ester; the fourth step is the tert-
butyl deprotection by triflouroacetic 
acid to form the corresponding 
tris(3,5-dibromosalicylate) ester. The desired product was characterized by 1H 
and 13C NMR (Figure 28): The three hydrogen resonances at chemical shift 8 
8.43 and 8.03 are due to the isophthalate benzene groups, the six hydrogen 
peaks at 8 8.26, 8.20, 8.06 and 8.01 ppm are due to the aspirin's benzenes, 
the two hydrogen resonances at 8 5.39 are attributed to the methylene groups; 
the two peaks at 8 166.16 and 163.50 are assigned to the carbonyl carbons on 
the isophthalate aromatic ring, the two peaks at 8 163.47 and 162.21 to the 
carbonyl carbons on the aspirin aromatic rings, the multiple peaks at 8 158.15 -
119.18 to the isophthalate and aspirin aryl carbons and a peak at 8 65.36 to the 
methylene carbon. The synthesis of the reagent was successful. 
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It was confirmed that the crosslinking reaction of hemoglobin with tris(3,5-
dibromosalicyl) trimesate DBSTM was at Lys82ps and few tri-linking involved 
Va11P, the third 3,5-dibromosalicylate 
ester principally undergoes hydrolysis 
instead of reaction with the a-amino 
group of a Valfi1 [78]. The tri-linking 
reaction of hemoglobin with DBCPA, 
whose structure is similar to DBSTM, 
was studied at the specific site of Tris(3,5-dibromosalicyl) trimesate 
Lys82ps and Val1/J, using computer modeling. As shown in Figure 24, 
DBCPA functional groups is closest to the amino groups of the residues of which 
the specific site comprises. This reaction can be understood in terms of a 
molecular model. The distance from the reactive carbonyl carbons to the a-
amino group is 1.45 A longer than to either of the &N's of the two Lys82ps. 
DBCPA provides the possible tri-linking at the BPG site in hemoglobin because 
its longer middle arm is able to reach a Valfi1 to react. The good fit of DBCPA at 
the specific site needs less activation energy for reaction of hemoglobin with the 
reagent to favor tri-linking of hemoglobin than those of DBSTC and DBSTM 
(Table 10). 
The ion-exchange chromatography of the crosslinked derivatives with 
tris(3,5-dibromosalicyl) (3,5-dicarboxy phenoxy) acetate (Figure 29a) isolated 
Table 10. Distances between ester carbonyl carbons of DBSTC, DBSTM 
and DBCPA. 
Crosslinker Distance (A) 
DBSTC 3.3 3.8 4.6 
SMPTM 5.1 5.1 5.2 
DBSTM 5.1 5.1 5.1 
DBCPA 5.1 5.5 6.6 
Amide bond 2.35 
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two major products from deoxyhemoglobin reaction. The first peak eluted from 
the column contained only Hb A. The component of the second peak is bi-linked 
hemoglobin having a dimeric band (32,000 MW) on SOS-PAGE (Figure 29b and 
Table 8). The multiple dimeric bands indicate that the crosslinking reaction was 
heterogeneous because of the asymmetry of the reagent. The component of the 
third peak is probably tri-linked hemoglobin, because it has lost additional 
positively charged groups as shown by its mobility on both anionic-exchange 
chromatography (Figure 29 a) and alkaline agarose gel electrophoresis. The 
dimeric bands of SOS-PAGE corresponding to tri-linking indicated that the tri-link 
was between two p subunits, being consistent with the reaction site of Lys82's 
and Val1 as we expected. The SOS-PAGE also shows multiple bands at the 
dimeric range. This is due to the fact that OBCPA has two isophthalate aspirin 
ester (IAE1 and IAE2) and one acetate aspirin ester (AAE). The symmetry of 
OBCPA structure is point group C2h instead of C3h as the symmetry of OBSTM is. 
Therefore, the crosslinking of hemoglobin with OBCPA is a heterogeneous 
reaction which can go: (1) IAE1 ~ /J182, IAE2 ~ /3282, and AAE ~ P1; (2) IAE1 
~ /3182, IAE2 ~ P1, and AAE ~ /J282; (3) IAE1 ~ /J182, AAE ~ /J282, and 
IAE2 ~ P1: (4) AAE ~ /3182, IAE1 ~ /3282, and IAE2 ~ P1; (5) AAE ~ P182, 
IAE ~ P1, and AAE ~ /3282; .. . The possible bi- and tri-linking are shown in 
Figure 33. 
The OBCPA crosslinking of inter-subunit of hemoglobin improved the 
thermal stability significantly (Figure 30 and Table 9). The broad transition of 
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the hemoglobins was expected due to the presumed multi-state nature of the 
denaturation. When hemoglobin is thermally denatured, the most likely first 
step is the dissociation of the [apj2 tetramers into ap dimers followed by further 
dissociation into a and p monomers, and finally unfolding of the individual 
chains [71]. The covalent connection between the p chains of the DBCPA 
crosslinked proteins prevented tetramers from dissociation into ap dimers. The 
denaturation of the crosslinked hemoglobins underwent dissociation of tetramers 
into a monomers and p-p dimers as the first step which had to surmount a high 
energy barrier thermodynamically to overcome inter-subunit forces from two p 
chains and one a chain, while the denaturation of uncrosslinked hemoglobin 
surmounts low energy barriers to dissociate tetramers into ap dimers, and the 
dimers dissociates into monomers overcoming a inter-subunit force from only 
one p chain. The DBCPA crosslinking of hemoglobins resulted in a higher 
denaturation transition, t1. Tm = 14.0 °C, than native hemoglobin. However, the 
tri-linked hemoglobins did not exhibit more thermally stable than the bi-linked 
hemoglobins, indicating that inter-subunit tri-linked proteins have the same 
mechanism of denaturation as inter-subunit bi-linked proteins and have an 
equivalent dissociation energy to the later. 
Although autoxidation of hemoglobin (Hb-Fe(ll) ~ Hb-Fe(lll)) is a very 
complex reaction, the tests showed the autoxidation of native and the DBCPA 
crosslinked hemoglobins was linear within 17 h and precise to 10"7 h-1 order 
(Figure 31 and Table 9). Comparison of the autoxidation results of native and 
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the deoxy crosslinked hemoglobins indicates that the autoxidation rate of the 
crosslinked hemoglobins remained unchanged with the kapp at approximately 7.0 
x 10-2 h-1. According to this study and the previous work, we can found that 
crosslinking at the BPG binding site of hemoglobin does not change the 
autoxidation rate constant as much as crosslinking at other sites of hemoglobin 
[95]. It was reported that fumarate crosslinking at Lys82ps of oxyhemoglobin 
had a smaller kapp than crosslinking at Lys99a's of deoxyhemoglobin [95]. It can 
be thought that DBCPA crosslinking of deoxyhemoglobin holds the two fJ chains 
closer than they should be at the T state so that the R state quaternary structure 
was favored (96-97]. Hemoglobin in the R state is less susceptible to 
autoxidation than in the T state (26]. Unlike DBSF crosslinked hemoglobins (95], 
the rate of autoxidation is not correlated with oxygen affinity for the DBCPA 
modified hemoglobins. 
The DBCPA bi-linked hemoglobins had a lower oxygen affinity than native 
hemoglobin, while the tri-linked hemoglobins exhibit a higher oxygen affinity 
(Figure 32 and Table 9). Many studies showed that crosslinking at BPG binding 
site of hemoglobin changed the oxygen affinity of hemoglobin significantly (14, 
65, 69-70, 77, 79, 98-100]. When crosslinking of hemoglobin with reagents with 
small sizes, oxygen affinity usually increased (69, 77]. When crosslinking of 
deoxyhemoglobin with reagents with large sizes and rigid structures, oxygen 
affinity decreased [77, 79]. This is due to the fact that small reagents pull the two 
fJ chains, shifting (or keeping) the conformation of the hemoglobins in the R state 
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which favor oxygenation, while larger and rigid reagents prevent the p chains 
from coming close, holding the conformation of hemoglobin in the T state which 
favors deoxygenation. The decreased oxygen affinity of DBCPA bi-linked 
hemoglobins is consistent with the result of the bi-linked hemoglobins with 
tris(sodium methyl phosphate) trimesate (SMPTM) [79). However, the 
increased oxygen affinity of the DBCPA tri-linked proteins is inconsistent with 
that of the SMPTM tri-linked hemoglobin [79). According to Kluger's systematic 
studies in which different sizes of crosslinkers were used including bis(methyl 
phosphate) fumarate, isophthalate, terephthalate, trans-stilbene 3,3'-
dicarboxylic acid, and trans-stilbene 4,4' -dicarboxylic acid, oxygen affinity 
decreased with increase of bridging distance between Lys82ps of hemoglobin; 
oxygen affinity increased with increase of bridging distance between Lys82P1 
and Val1fh of hemoglobin [77). The SMPTM crosslinking distance between 
Lys82P1 and Val1fh is 7.8 A and that of DBCPA can be up to 9.3 A (Table 10). 
Therefore, in tri-linking of hemoglobin, the bridging distance between Lys82P1 
and Val1fh is still a factor to affect the oxygen affinity of hemoglobin. The 
DBCPA tri-linked proteins had a half-fold n compared to native hemoglobin, 
indicating that the multi-linking of hemoglobin made the conformation of the 
hemoglobins less flexible, therefore less cooperative, than native hemoglobin. 
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The low oxygen affinity of DBCPA bi-linked hemoglobins also indicates 
the possibility that the crosslinking of hemoglobin was between Val1/J1 and 
Lys82/h with 3,5-dicarboxy of the tri-linker. 
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Figure 24. (A) DBSTC, (B) DBSTM and (C) DBCPA in the BPG binding site. 
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Figure 25. 1H and 13C NMR of (3,5-dicarboxy phenoxy) acetic acid 
(DMSO-ds). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 26. 1H and 13C NMR of (3,5-dicarboxy phenoxy) acetyl trichloride 
(CDCb). 
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(a) 1H NMR. 
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Figure 27. 1H and 13C NMR of tris(tert-butyl 3, 5-dibromosalicylate) (3,5-
dicarboxy phenoxy) acetate (CDC'3). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 28. 1H and 13C NMR of tris(3, 5-dibromosalicyl) (3,5-
dicarboxy phenoxy) acetate (DMSO-d6). 
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(b) 13C NMR. 
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Figure 29. Anion-exchange chromatography and SOS-PAGE of hemoglobin 
crosslinked by DBCPA. 
(a) Ion-exchange chromatography. 
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Figure 30. Denaturation of native and DBCPA crosslinked hemoglobins. 
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Figure 31. Autoxidation of native and DBCPA crosslinked hemoglobins. 
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Figure 32. Oxygen dissociation curves of fresh blood, native and DBCPA 
crosslinked hemoglobins. 
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Figure 33. Symbolic representation of possibly doubly and triply linked 
products of DBCPA reacting with hemoglobin. 
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Chapter 6 
ELONGATED TETRA-LINKERS AND INTERMOLECULAR 
CROSSLINKING OF HEMOGLOBIN 
RESULTS 
The first section of this chapter summarizes the analytical results for each of 
the compounds synthesized. The spectra are given at the end of the chapter. 
5,5'-(1,3-Propanedioxy) diisophthalic acid 
Decomposition: 300 °c. 
1H NMR (DMSO-d6) (see Figure 34 (a)): 8 (ppm) 8.06 (t, 2H, ArH), 7.66 (d, 4H, 
ArH), 4.25 (t, 4H, O-CH2), 2.22 (m, 2H, CH2) 
13C NMR (DMSO-d6) (see Figure 34 (b)): 8 (ppm) 166.44 (s, 4C, C=O), 158.63 (s, 
2C, 0-ArC), 132.70 (s, 4C, ArC), 122.31 (s, 2C, ArC), 119.07 (s, 4C, ArC), 64.84 
(s, 2C, O-CH2), 28.40 (s, 1C, CH2). 
5,5'-(1,3-Propanedioxy) diisophthalyl tetrachloride 
Melting point: 104.5-105.5 °C. 
1H NMR (CDCl3) (see Figure 35 (a)): 8 (ppm) 8.44 (t, 2H, ArH), 7.90 (d, 4H, ArH), 
4.33 (t, 4H, O-CH2), 2.41 (m, 2H, CH2). 
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13C NMR (CDCb) (see Figure 35 (b)): o (ppm) 167.08 (s, 2C, C=O), 159.32 (s, 2C, 
0-ArC), 135.43 (s, 2C, ArC), 126.27 (s, 4C, ArC), 122.63 (s, 4C, ArC), 65.08 (s, 
2C, O-CH2), 28.73 (s, 1C, CH2). 
Tetrakis( tert-butyl 3,5-dibromosalicyl) 5,5' -( 1,3-propanedioxy) diisophthalate 
Melting point: 127-130 °C. 
1H NMR (CDCb) (see Figure 36 (a)): o (ppm) 8.68 (s, 2H, ArH), 8.04 (d, 4H, ArH), 
8.02 (d, 4H, ArH), 7.92 (d, 4H, ArH), 4.36 (t, 4H, O-CH2), 2.42 (m, 2H, CH2), 1.39 
(s, 36H, tBu). 
13C NMR (CDCb) (see Figure 36 (b)): o (ppm) 162.76 (s, 4C, C=O), 162.15 (s, 2C, 
C=O), 159.54 (s, 2C, 0-ArC), 146.84 {s, 4C, 0-ArH), 139.09 (s, 4C, ArH), 133.94 
(s, 4C, ArH), 131.19 (s, 4C, ArH), 129,26 (s, 4C, ArC), 125.09 (s, 2C, ArC), 121.65 
(s, 4C, ArC), 119.86 (s, 4C, ArC), 119.50 (s, 2C, ArC), 83.44 (s, 4C, 0-C), 65.29 
(s, 2C, O-CH2), 29.60 (s, 1C, CH2), 28.25 (s, 12C, tBu). 
Tetrakis(3,5-dibromosalicyl) 5,5' -( 1,3-propanedioxy) diisophthalate 
Melting point: 175-180 °C. 
1H NMR (DMSO-de) (see Figure 37 (a)): o {ppm) 8.38 (s, 2H, ArH), 8.31 (s, 4H, 
ArH), 8.09 (s, 4H, ArH), 8.02 (s, 4H, ArH), 4.41 (t, 4H, O-CH2), 2.30 (m, 2H, 
CH2). 
13C NMR (DMSO-d6) (see Figure 37 (b)): o (ppm) 163.40 (s, 4C, C=O), 162.26 (s, 
2C, C=O), 159.28 {s, 2C, 0-ArC), 146.66 (s, 4C, 0-ArC), 138.90 (s, 4C, ArC), 
133.43 (s, 4H, ArC), 130.44 (s, 4C, ArC), 127.60 (s, 4C, ArC), 123.00 (s, 2C, 
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ArC), 121.06 (s, 4C, ArC), 119.39 (s, 4C, ArC), 119.29 (s, 4C, ArC), 65.48 (s, 
2C, O-CH2), 27.37 (s, 1C, CH2). 
5,5' -Triethyleneglycol diisophthalic acid ether 
Decomposition: 302 °C. 
1H NMR (DMSO-ds) (see Figure 38 (a)): o (ppm) 8.05 (t, 2H, ArH), 7.63 (d, 4H, 
ArH), 4.19 (t, 4H, O-CH2), 3.77 (t, 4H, O-CH2), 3.62 (s, 4H, O-CH2). 
13C NMR (DMSO-ds) (see Figure 38 (b)): o (ppm) 166.40 (s, 2C, C=O), 158.66 (s, 
2C, 0-ArC), 132.61 (s, 4H, ArC), 122.35 (s, 2C, ArC), 70.02 (s, 2C, O-CH2), 68.88 
(s, 2C, O-CH2), 67.85 (s, 2C, O-CH2). 
5,5' -Triethyleneglycol diisophthalyl ether tetrachloride 
1H NMR (CDCb) (see Figure 39 (a)): o (ppm) 8.41 (t, 2H, ArH), 7.88 (d, 4H, ArH), 
4.24 (t, 4H, O-CH2), 3.90 (t, 4H, O-CH2), 3.75 (s, 4H, O-CH2). 
13C NMR (CDCb) (see Figure 39 (b)): o (ppm) 167.10 (s, 2C, C=O), 159.52 (s, 2C, 
O-CH2), 135.28 (s, 2C, ArC), 126.19 (s, 4C, ArC), 122.94 (s, 4C, ArC), 70.96 (s, 
2C, O-CH2), 69.53 (s, 2C, O-CH2), 68.63 (s, 2C, O-CH2). 
Tetrakis( tett-3,5-dibromosalicyl) 5,5' -triethyleneglycol diisophthalate ether 
Melting point: 95-98 °c. 
1H NMR (CDCb) (see Figure 40 (a)): o (ppm) 8.66 (t, 2H, ArH), 8.03 (d, 4H, ArH), 
8.00 (d, 4H, ArH), 7.90 (d, 4H, ArH), 4.28 (t, 4H, O-CH2), 3.92 (t, 4H, O-CH2), 
3.78 (s, 4H, O-CH2), 1.37 (s, 36H, tBu); 
13C NMR (CDCb) (see Figure 40 (b)): o (ppm) 162.44 (s, 4C, C=O), 161.84 (s, 
2C, C=O), 159.29 (s, 2C, 0-ArC), 146.49 (s, 4C, 0-ArC), 138.76 (s, 4C, ArC), 
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133.62 (s, 4C, ArC), 130.76 (s, 4C, ArC), 128.94 (s, 4C, ArC), 124.77 (s, 2C, 
ArC), 121.53(s, 4C, ArC), 119.52(s, 4C, ArC), 119.15(s, 4C, ArC), 83.13(s, 
4C, 0-C), 70.98 (s, 2C, O-CH2), 69.59 (s, 2C, O-CH2), 68.29 (s, 2C, O-CH2), 
27.92 (s, 12C, tBu). 
Tetrakis(3,5-dibromosalicyl) 5,5-triethyleneglycol diisophthalate ether 
Melting point: 157-160 °C. 
1H NMR (DMSO-d6) (see Figure 41 (a)): B (ppm) 8.37 (s, 2H, ArH), 8.32 (d, 4H, 
ArH), 8.09 (d, 4H, ArH), 7.99 (s, 4H, ArH), 4.32 (m, 4H, O-CH2), 3.79 (m, 4H, 
O-CH2), 3.64 (s, 4H, O-CH2). 
13C NMR (DMSO-ds) (see Figure 41 (b)): B (ppm) 163.41 (s, 4C, ArC=O), 162.25 
(s, 2C, ArC=O), 159.34 (s, 2C, 0-ArC), 146.55 (s, 4C, 0-ArC), 139.91 (s, 4C, 
ArC), 133.43 (s, 4C, ArC), 130.44 (s, 4C, ArC), 127.62 (s, 4C, ArC), 123.01 (s, 
2C, ArC), 121.17 (s, 4C, ArC), 119.34 (s, 4C, ArC), 119.28 (s, 4C, ArC), 69.99 
(s, 2C, O-CH2), 68.85 (s, 2C, O-CH2), 68.41 (s, 2C, O-CH2). 
5,5'-(1, 10-decanedioxy) diisophthalic acid 
1H NMR (DMSO-d6) (see Figure 42 (a)): B (ppm) 8.05 (s, 2H, ArH), 7.61 (s, 4H, 
ArH), 4.04 (t, 4H, O-CH2), 1.71 (m, 4H, CH2), 1.38 (m, 4H, CH2), 1.27(m, 8H, CH2). 
13C NMR (DMSO-d6) (see Figure 42 (b)): B (ppm) 166.11 (s, 4C, C=O), 158.56 (s, 
2C, ArC), 132.43 (s, 4C, ArC), 121.94 (s, 2C, ArC), 118.86 (s, 4C, ArC), 68.05 (s, 
2C, O-CH2), 28.92 (s, 2C, CH2), 28.69 (s, 2C, CH2), 28.48 (s, 2C, CH2), 25.37 (s, 
2C, CH2). 
5,5' -( 1, 10-decanedioxy) diisophthalate tetrachloride 
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1H NMR (DMSO-d6) (see Figure 43 (a)): B (ppm) 8.41 (s, 2H, ArH), 7.85 (s, 4H, 
ArH), 4.06 (t, 4H, O-CH2), 1.83 (m, 4H, CH2), 1.48 (m, 4H, CH2), 1.34 (m, SH, 
CH2). 
13C NMR (DMSO-d6) (see Figure 43 (b)): B (ppm) 167.01 (s, 4C, C=O), 159.73 (s, 
2C, ArC), 135.29 (s, 2C, ArC), 125.76 (s, 4C, ArC), 122.65 (s, 4C, ArC), 69.30 (s, 
2C, O-CH2), 29.50 (s, 2C, CH2), 29.34 (s, 2C, CH2), 29.00 (s, 2C, CH2), 25.99 (s, 
2C, CH2). 
SOS-PAGE of the crosslinked hemoglobins 
SOS-PAGE analysis (Figure 44 and 45) of the crosslinked hemoglobins 
exhibits 46% dimer, 2% trimer and 1 % tetramer for crosslinking by tetrakis(3,5-
dibromosalicyl) 5,5'-(1,3-propanedioxy) diisophthalate; 44% dimer, 12% trimer and 
5% tetramer for crosslinking by tetrakis(3,5-dibromosalicyl) 5,5-triethyleneglycol 
diisophthalate ether; and 43% dimer, 6% trimer and 1 % tetramer for crosslinking by 
tetrakis(sodium methyl phosphate) 5,5'-(1, 10-decanedioxy) diisophthalate (Table 
11). 
Table 11. SOS-PAGE analysis of the DBPDI, DBTDI and SMPDI crosslinked 
hemoglobins by gel scanner. 
Sample % Dimer % Trimer % Tetramer 
DBPDl-XL 46 2 1 
DBTDE-XL 44 12 5 
SMPDl-XL 43 6 1 
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DISCUSSION 
The tetrakis(3,5-dibromosalicyl) linkers, DBPDI, DBEIE and SMPDD, 
were designed to tetra-link between two tetrameric hemoglobins and between 
Lys82ps of each tetramer to form a octamer in one step (Scheme XII). 
Previously described crosslinkers with two meta 3,5-dibromosalicyl ester groups 
[77-78] or sodium methyl phosphate groups [79] showed high selectivity for 
reaction at the site between Lys82ps of hemoglobin. In the structures of the 
elongated tetra-linkers, each end contains two meta 3,5-dibromosalicyl ester 
groups which are sterospecific to crosslink between Lys82ps of one hemoglobin 
molecule. Reaction of the tetra-linkers with hemoglobin in one step simplifies the 
process of synthesis of a specifically modified octameric hemoglobin. 
The syntheses of both tetrakis(3,5-dibromosalicyl) 5,5-(1,3-propanedioxy) 
diisophthalate (DBPDI) and tetrakis(3,5-dibromosalicyl) 5,5-triethyleneglycol 
diisophthalate ether (DBEIE) have four steps. The first step is the production of 
diisophthalic acids; the second step is the production of the corresponding acid 
chlorides; the third step is the production of the corresponding tetrakis(3,5-
dibromosalicylate) esters; the fourth step is the tert-butyl deprotection by 
trifluoroacetic acid to form the corresponding tetrakis(3,5-dibromosalicyl)esters. 
The tetrakis(3,5-dibromosalicyl) 5,5'-(1,3-propanedioxy) diisophthalate was 
characterized by 1H and 13C NMR (Figure 37): The six hydrogen resonances at 
chemical shifts 8 8.38 and 8.02 ppm are assigned to the isophthalate aryl 
Scheme XII. 
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hydrogens, the eight hydrogen resonances at o 8.31 and 8.09 ppm are the aspirin 
benzenes and the six hydrogen resonances at o 4.41 and 2.300 ppm to the 
methylene groups; the two peaks at o 163.40 and 162.26 ppm are assigned to the 
carbonyl carbons on the aspirin and isophthalate aromatic rings, the ten peaks at o 
159.28 - 119.29 ppm to the aspirin and isophthalate aryl carbons and two peaks at o 
65.48 - 27.37 ppm to the methylene carbons. The synthesis of the reagent was 
successful. 
The desired product for tetrakis(3,5-dibromosalicyl) 5,5-triethyleneglycol 
isophthalate ether was characterized by 1H and 13C NMR (Figure 41): The six 
hydrogen resonances at chemical shifts o 8.37 and 7.99 ppm are assigned to the 
isophthalate benzenes, the eight hydrogen resonances at o 8. 32 and 8. 09 ppm to 
the aspirin benzenes and the twelve hydrogen resonances at o 4.32, 3.79 and 3.64 
ppm to the ethyleneglycol groups; the two peaks at o 163.41 and 162.25 ppm are 
assigned to the carboxyl carbons on the aspirin and isophthalate aromatic rings, the 
ten peaks at o 159.34 - 119.28 ppm to the aspirin and isophthalate aryl carbons and 
the three peaks at o 69.99, 68.85 and 68.41 ppm are the ethyleneglycol carbons. 
The synthesis of the reagent was successful. 
The preparation of tetrakis(sodium methyl phosphate) 5,5-(1, 10-
decanedioxy) diisophthalate (SMPDI) has four steps. The first step is the production 
of diisophthalic acids; the second step is the production of the corresponding acid 
chlorides; the third step is the production of the corresponding tetrakis( dimethyl 
phosphate); the fourth step is the production of the corresponding tetrakis(sodium 
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methyl phosphate). The product is soluble in water. The results of NMR 
characterization of tetrakis(sodium methyl phosphate) 5,5-(1, 10-decanedioxy) 
diisophthalate were not satisfactory because of the low solubility of the compound in 
deuterium oxide. 1H NMR shows multiple peaks around o 4 ppm corresponding to 
the methoxy of phosphate and o 1.5 ppm to decylene. 
The results of SOS-PAGE in Figure 44 show that OBPOI and OBEIE can 
intramolecularly crosslink very effectively, but intermolecular crosslinking is slight. 
The amount of triply and quadruply crosslinked species demonstrates the difficulties 
in having a second reaction once one end of the reagent has reacted with a BPG 
binding site. In addition, it is not certain that the trimers and tetramers observed 
upon SOS-PAGE actually represent intermolecular crosslinking. It is possible that 
there is little reaction with the a-chains of crosslinked tetramer. OBEIE gave higher 
yields of trimer and tetramer because of its longer size and greater solubility in 
aqueous solution than OBPOI (Tables 11 and 12). The reaction of hemoglobin with 
another kind of tetralinker, SMPOI, also produced double, triple and tetra-linking 
(Figure 45 and Table 11 }, but it was less effective than OBEIE. While the methyl 
phosphate groups should provide water solubility for the termini of SMPDI, the ten 
methylene groups in the connecting region are more hydrophobic than the bridging 
structure of OBEIE and it folds in aqueous solution making the bridging length of the 
reagent much shorter than expected (Table 12). 
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Table 12. Bridging lengths between ester carbonyl carbons of the tetra-linkers 
Compound Bridging length (A) 
DBPDI 5.1 5.2 10.7 10.7 13.3 13.7 
DBEIE 5.1 5.1 15.4 16.9 18.1 20.1 
SMPDI 5.2 5.2 18.8 20.0 21.3 23.0 
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The successful tetra-linking of hemoglobin would provide a new method to 
crosslink hemoglobin intramolecularly between two p chains and intermolecularly 
between two hemoglobin molecules at one step to produce a novel blood substitute, 
thermally stable octameric hemoglobin (Scheme XII). DBEIE appears to be the best 
of the three reagents developed here, but better reaction conditions need to be 
developed before it can be used to efficiently produce hemoglobin octamers. 
Figure 34. 1H and 13C NMR of 5,5'-(1,3-propanedioxy) diisophthalic acid 
(DMSO-ds). 
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Figure 35. 1H and 13C NMR of 5,5'-(1,3-propanedioxy) diisophthalyl 
tetrachloride (CDC'3). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 36. 1H and 13C NMR of tetrakis(tett-butyl 3,5-dibromosalicyl) 5,5'-(1,3-
propanedioxy) diisophthalate (CDC'3). 
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(a) 1H NMR. 
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Figure 37. 1H and 13C NMR of tetrakis(3,5-dibromosalicyl) 5,5'-(1,3-
propanedioxy) diisophthalate (DMSQ-d3). 
180 
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Figure 38. 1H and 13C NMR of 5,5'-triethyleneglycol diisophthalic acid ether 
(DMSO-ds). 
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Figure 39. 1H and 13C NMR of 5,5'-triethyleneglycol diisophthalyl ether 
tetrachloride (CDC'3). 
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(b) 13C NMR. 
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Figure 40. 1H and 13C NMR of tetrakis(tett-3,5-dibromosalicyl) 5,5'-
triethyleneglycol diisophthalate ether (CDCla). 
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Figure 41. 1 H and 13C NMR of tetrakis(3,5-dibromosalicyl) 5,5-triethyleneglycol 
diisophthalate ether (DMSO-d6). 
(a) 1H NMR. 
(b) 13C NMR. 
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Figure 42. 1H and 13C NMR of 5,5'-(1,10-decanedioxy) diisophthalic acid 
(DMSO-ds). 
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Figure 43. 1H and 13C NMR of 5,5'-(1, 10-propanedioxy) diisophthalate 
tetrachloride (CDC'3). 
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(a) 1H NMR. 
(b) 13C NMR. 
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Figure 44. SOS-PAGE of the DBPDI and DBTDE crosslinked 
hemoglobins. 
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Figure 45. SOS-PAGE of the SMPDI crosslinked hemoglobins. 
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Chapter 7 
STUDY ON THE POSSIBILITY OF CROSSLINKING 
IN HEMOGLOBIN CRYSTALS 
RESULTS AND DISCUSSION 
Computer modeling and design 
The production of crosslinked octamers in solution is difficult because the 
distance between two tetrameric hemoglobins is not fixed so that size of 
crosslinking reagent is difficult to design. When hemoglobin is in the crystalline 
state, the distance between the two tetramers in a unit cell is fixed and much 
shorter than in solution. The arrangement of molecules in the unit cell is shown 
in Figure 46. A model of the crystal packing comprising six deoxyhemoglobin 
molecules (Figure 47) shows that the space filled with water [87-89] between 
hemoglobin molecules provides pathways for small molecules to diffuse inside 
the crystals. In these channels there are possible sites composed of several e-
amino groups of lysines with which crosslinking reagents would be able to react. 
198 
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Figure 46. A stereo view of the crystal unit of deoxyhemoglobin in P21 space 
group. 
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Figure 47. A model of crystal packing composed of six deoxyhemoglobin 
molecules. 
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Lysa.7, and Lysa.11 on one tetramer and LysJ366 on another could be a possible 
specific site for crosslinking between the two tetramers (Figure 48). The tri-
linker, tris(3,5-dibromosalicyl) tricarballylate, was designed with the suitable 
size to react at this site (Figure 49). 
Reaction of hemoglobin with bis(3,5-dibromosalicyl) fumarate in 
crystallization conditions 
Reaction of hemoglobin with bis{3,5-dibromosalicyl) fumarate (OBSF) has 
been well studied [69-72]. To determine if this type of reagents can be used to 
modify crystallized hemoglobin, the reaction was done under crystallization 
conditions [90]. The analysis of SOS-PAGE given in Table 13 indicates that 
OBSF crosslinked between two chains of hemoglobin under both high salt 
(sample 1 and 2) and low salt (sample 3 and 4) crystallization conditions. The 
yields of crosslink in the high salt concentrations, however, were less than in 
the low salt concentrations. This result may be due to reaction of ammonium 
ions in the high salt buffer with the OBSF. 
Reaction of crystallized hemoglobin with tris(3,5-dibromosalicyl) 
tricarballylate and bis(3,5-dibromosalicyl) fumarate 
We used tris(3,5-dibromosalicyl) tricarballylate to react with crystallized 
hemoglobin from the high-salt condition. The result of SOS-PAGE did not show 
any dimer formation. The same reagent reacted with crystallized hemoglobin 
from the low-salted condition and also had no reaction. No crosslinking was 
obtained either when OBSF was used to react with crystallized hemoglobin from 
both high-salt and low-salt conditions. 
Figure 48. Expanded view of the crystal model at the possible specific-
site. 
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Figure 49. The size of tris(3,5-dibromosalicyl) tricarballylate. 
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Table 13. SOS-PAGE analysis of DBSF crosslinking reaction under 
crystallization conditions. 
Sample Condition % Monomer % Dimer 
2.3 M (NH4)2$Q4 65 35 
0.3 M (NH4)2P04 
1 
~------------------------------- ---------------
Controlled test 100 0 
w/o crosslinker 
2 1.5 M (NH4)2$Q4 59 41 
0.4 M (NH4)2P04 
8% PEG-6000* 
100 mM KCI 46 54 
10mM ~HPQ4 
3 
------------------"""------------- --------------
Controlled test 100 0 
w/o crosslinker 
16% PEG-600 
4 100 mM Na cacodylate 50 50 
75mM NaCl 
* PEG-6000: Polyethylene glycol 6000. 
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The failure of crosslinking of crystallized hemoglobin might be due to one 
or more of the following causes: 
( 1) The reagents with the aspirin leaving groups are too large to diffuse in the 
channels between hemoglobin molecules. 
(2) The solubility of the reagents in aqueous solution is too low, especially 
under high salt conditions, to make the high gradient of the reagents to drive 
them into the crystals. 
(3) The transportation and crosslinking of the reagents in the crystals is much 
more complicated than we expected. 
If the failure is a result of (1) and/or (2), crosslinking of crystallized 
hemoglobin would be still possible if a smaller reagent can be found which is 
soluble in aqueous solution and specific for the reaction site. Alternatively, 
forming smaller aggregates of hemoglobin under near crystallization conditions 
may be a better approach to solve this problem. 
REFERENCES 
1. Slovifer, H. A. and Kamimoto, T., Nature, 1967, 216, 458-460. 
2. Slovifer, H. A., Yamada, H. and Ogashi, S., Federation Proceedings, 1970, 
29, 1755-1757. 
3. Kitayawce, M. and Ohnishi, Y., Virchows Archives, 1982, 398, 1-10. 
4. Bolton, W. and Perutz, M. F., Nature, 1970, 228, 551-552. 
5. Fermi, G. and Perutz, M. F., J. Mo/. Biol., 1984, 175, 159-174. 
6. Shaanan, B., J. Mo/. Biol., 1983, 171, 31-59. 
7. Dickerson, R. E. and Geis, I., Hemoglobin: Structure, Function, Evolution 
and Pathology, The Benjamin/Cummings Publishing Co. Inc.; Menlo Park, 
California; Reading, Massachusetts; London, Amsterdam, Don Mills, 
Ontario, Sydney, 1983, 20-26. 
8. Stryer, L., Biochemistry, 4th Ed, W. H. Freeman and Company, New York, 
1995, 147-164. 
9. Antonini, E. and Brunori, M., Hemoglobin and Myoglobin in their Reactions 
with Ugands, North Holland, Amsterdam, 1971. 
10. Voet, D. and Voet J. G., Biochemistry, John Wiley & Sons, Inc., 1990, 180-
181. 
11. Tanford, C., Adv. Protein Chem., 1968, 23, 121-126. 
12. Pace, C. N., CRC Grit. Rev. Biochem., 1975, 3, 1-5. 
13. Olsen, K. W., Methods in Enzymology, 1994, 231, 514-524. 
14. Benesch, R. E. and Kwong, S., J. Protein Chem., 1991, 10, 503-509. 
210 
211 
15. Schwartz, J. M., Reiss, A. L. and Jaffe, E. R., Metablic Basis of Inherited 
Diseases, 1984, 1654. 
16. Bunn, H. F. and Forget, B. G., Hemoglobin, Molecular, Genetic and Clinical 
Aspects, 1986, 634-662. 
17. Yang, T. and Olsen, K. W., Enzvmatic protection from Autoxidation for 
Cross/inked hemoglobins. Art. Cells, Blood subs., and lmmob. Biotech., 
1994, 22, 709-717. 
18. Mansouri, A., J. Med. Sci., 1985, 289, 200-209. 
19. White, J. R. and Dacie, J. V., Prog. Hematol., 1971, 7, 69-109. 
20. Sugawara, Y., Sakoda, M., Shibata, N. and Sakamoto, H., Japanese J. 
Physiology, 1993, 43, 21-34. 
21. Winterbourn, C. C., Semin. Hematol., 1990, 27, 41-50. 
22. Sugawara, Y. and Shikama, K., Eur. J. Biochem., 1980, 110, 241-246. 
23.Ackers, G. K. and Halvorson, H. R., Proc. Natl. Acad. Sci., U. S. A., 1974, 
71, 4312. 
24. Perutz, M. F., Kilmartin, J. V., Nishikura, K., Fogg, J. H., Butler, P. J. G. 
and Rollema, H. S., J. Molec. Biol., 1980, 138, 649-. 
25. Winslow, R. M. and Charache, S., J. Biol. Chem., 1975, 250, 6939-. 
26. Wallace, W. J., Houtchens, R. A., Maxwell, J. C. and Caughey, W. S., J. 
Biol. Chem., 1982, 257, 4866-4977. 
27. Olsen, J. S., Heme Loss from Myog/obin and Hemoglobin and Its Relation 
to Protein Stability. poster, The 38th Biophysical Society Meeting, New 
Orlean, Louisiana, 1994. 
28. Bolin, R. B., Geyer, R. P. and Nemo, G. J., Advances in Blood Substitute 
Research, Progress in Clinical and Biological Research Volume 122, Alan R. 
Liss, Inc., New York, 1983. 
29. Chang, T. M. S. and Geyer, R. P., Blood Substitutes, Marcel Dekker, Inc., 
new York, 1989. 
212 
30.Amberson, W. R., Blood Substitutes. Biol. Rev., 1937, 12, 48-55. 
31. Devenuto, F., Hemoglobin solution as Oxygen-Delivering Resuscitation 
fluids, Grit. Care Med., 1982, 10, 238-237. 
32. Perutz, M. F., Haemoglobin Behaves as an Allosteric Protein. Prog. clin. 
Biol. Res., 1975, 1, 3-10. 
33. Adair, G. S., Barcroft, J. and Bock, A. V., The Identify of Haemoglobin in 
Human beings. J. Physiol., 1921, 55, 332-340. 
34.Arnone, A., X-Ray Diffraction study of binding 2.3-BPG to Human 
Deoxyhemoglobin. Nature, 1972, 273, 146-151. 
35. Bunn, H. F. and Jandl, J. H., The Renal Handling of Hemoglobin. Trans. 
Assn. Am. Physicians, 1968, 81, 147-153. 
36. Bolin, R. B., Geyer, R. P. and Nemo, G. J., Advances in Blood Substitute 
Research, Alan R. Liss, Inc., New York, NY, 1982, 1-17. 
37. Looker, D., Abbott-Brown, D., Cozart, P., Durfee, S., Hoffman, S., 
Mathews, A. J., Miller-Roehrich, J., Shoemaker, S., Trimble, S., Fermi, 
G., Komiyama, N. H., Nagai, K. and Stetler, G. L., Nature, 1992, 356, 
258-260. 
38. Fronticelli, C., Brinigar, W. S., Olson, J. S., Bucci, E., Cryczynski, Z., 
O'Donnell, J. K. and Kowalczyk, J., Biochemistry, 1993, 32, 1135-1142. 
39. Chang, T. M. S., Science, 1964, 146, 524-531. 
40. Chang, T. M. S., Fed. Proc., 1969,28, 461 (abstract). 
41. Chang, T. M. S., Canadian Patent, 1971, 873, 815-122. 
42.Chang, T. M. S., Artificial Cells, Charles C Thomas, Springfield, IL, 1972. 
43. Chang, T. M. S., Appl. Bio/chem. & Biotechnol., 1984, 10, 5-12. 
44. Djordjevich, L. and Miller, I. F., Synthetic Ervthrocyfes from Lipid 
Encapsulated Hemoglobin. Exp. Hematol., 1980, 8, 584-592. 
45. Szebeni, J., Di Iorio, E. E., Hauser, H. and Winterhalter, K. H., 
Encapsulation of Hemoglobin in Phospholipid Liposomes: Characterization 
and Stability, Biochem, 1985, 24, 2827-2832. 
213 
46. Tam, S. C., Blumenstein, J., Wang, J. T. F., Proc. Natl. Acad. Sci. USA, 
1976, 73, 2128-2131. 
47. Tam, S. C., Blumenstein, J. and Wang, J. T. F., Can. J. Biochem., 1978, 
56, 981-984. 
48. Chang, J. E. and Wang, J. T. F., Can. J. Biochem., 1977, 55, 398-403. 
49. Prouchayret, F. and Dellachrie, E., Biopolymers, 1993, 33, 1803-1809. 
50.Ajisaka, K. and Iwashita, Y., Biochem. Biophys. Res. Commun., 1980, 97, 
1076-1078. 
51. Leonard, M. and Dellacherie, E., Biochem. Biophys. Acta., 1984, 791, 219-
225. 
52. Gould, S. A., Rosen, A. C., Sehgak, L., Noud, G., Sehgal, H., DeWoskin, 
R., Levine, H., Kerstein, M., Rice, C. and Moss, G. S., J. Surg. Res., 
1980, 28, 246-251. 
53. Moore, G. L., Ledford, M. E. and Tillotson, J. A., Molecular Heterogeneity of 
Pyridoxylated Polymerized Hemoglobin, San Fruncisco: Letterman Army 
Institute of Research Report, 1986, 227-234. 
54. Devenuto, F., Busse, K. R. and Zegna, A. I., Surg. Gynecol. Obstet., 1981, 
153, 332-336. 
55. Marini, M. A., Moore, G. L., Fishman, R. M., Jessee, R., Medina, F., Snell, 
S. and Zegna, A. J., Biopolymers, 1990, 29, 71-82. 
56.Agostoni, A., Stabilini, R., Perrella, M., Pietta, P. G., Pace, M., Russo, V. 
and abbioneda, L., Trans. Am. Soc. Artif. Intern. Organs., 1987, 33, 372-
373. 
57. Hisa, C. J. C., In The Red Cell: Severnth Ann. Arbor Conference, (G. 
Brewer, Ed), New York: Alan R. Liss, 339-349. 
58. Mok, W., Chen, D. E. and Mazur, A. I., Fed. Proc., 1975, 34, 1458-1460. 
59. Benesch, R. E., Benesch, R., Renthal, R. D. and Maeda N., affinity Labeling 
of the Polyphosphate Binding site of Hemoglobin. Biochemistry, 1972, 11, 
2568-2577. 
214 
60. Benesch, R. and Benesch, R. E., Biochem. Biophys. Res. Commun., 1967, 
26, 162-167. 
61. Benesch, R., Benesch, R. E., Yung, S. and Edalji, R., Biochem. Biophys. 
Res. Commun., 1975, 63, 1123-1129. 
62. Benesch, R., and Benesch, R. E., Methoods in Enzymology, Hemoglobin, 
1981, 76, 147-159. 
63. Benesch, R., Triner, L., Benesch, R. E., Kwong, S., Verosky, M., Proc. 
Natl. Acad. Sci. USA, 1984, 81, 2941-2943. 
64. Bleeker, W. K., Van Der Plas, J., Agterberg, J., Rigter, G., Bakker, J. C., 
J. Lab. Clin. Med., 1986, 108, 448-455. 
65. Benesch, R. E. and Kwong, S., Biochem. Biophys. Res. Commun., 1988, 
156, 9-14. 
66. Keipert, P. E., Adeniran, A. J., Kwong, S. and Benesch, R. E., Transfusion, 
1989, 29, 768-773. 
67.Zaugg, R. H., King, C. L. and Klotz, I. M., Biochem. Biophys. Res. 
Commun., 1975, 64, 1192-1198. 
68. Walder, J. A., Zaugg, R. Y., Steele, J. M. and Klotz, I. M., Biochemistry, 
1979, 18, 4265-4273. 
69. Walder, J. A., Walder, R. and Arnone, A., J. Mo/. Biol., 1980, 141, 195-
216. 
70. Chatterjee, R., Aelt, R. V., Walder, R. Y., Pruit, S. L., Rogers, P. H., 
Arnone, A. and Walder, J. A., J. Biol. Chem., 1986, 261, 9927-9937. 
71. White, F. L. and Olsen, K. W., arch. Biochem. Biophys., 1987, 258, 51-57. 
72. Yang, T. and Olsen, K. W., Arch. Biochem. Biophys, 1988, 261, 283-290. 
73. Huang, H. and Olsen, K. W., Art. Cells. Blood Subs., and lmmob. Biotech., 
1994, 22, 719-724. 
74. Kluger, R., Grant, A. S., Bearne, S. L. and Trachsel, M. R., J. Org. Chem., 
1990, 55, 2864-2868. 
75. Kluger, R. and Tsui, W. C., J. Org. Chem., 1980, 45, 2723. 
215 
76. Ueno, H., Pospischil, M. A Manning, J. M. and Kluger, R., Arch. Biochem. 
Biophys., 1986, 244, 795-804. 
77. Jones, R. T., Head, C. G., Fujuta, T. S., Shih, D. T.-B., Wodzinska, J. and 
Kluger, R., Biochemistry, 1993, 32, 215-223. 
78. Kluger, R., Song, Y.-H., Wodzinska, J., Head, C., Fujita, T. S., Jones, R. 
T., J. Am. chem. Soc., 1992, 114, 9275-9279. 
79. Kluger, R., Wodzinska, J., Jones, R. T., Head, C., Fujita, T. S. and Shih, D. 
T., Biochemistry, 1992, 31, 7551-7559. 
80. Van Orie, J. H., Weininger, D. and Martin, Y. C., J. Comput-Aided Mo/. Des., 
1989, 3, 225-230. 
81. Delaney, E. J., Massil, S. E., Shi, G., and Klotz, I. M., Alternative Diaspirins 
for Modification of Hemoglobin and Sickle Hemoglobin, Archives of Biochem. 
and Biophys., 1984, 228, 627-638. 
82. Dozy, A M., Kleihaner, E. F and Hilisman, T. H. J., J. Chromatog., 1968, 32, 
723-727. 
83. Huisman, T. H.J. and Dozy, AM., J. Chromatog., 1965, 19, 160-169. 
84. Assendelft, 0. W. V. and Eulstra, W. G., Anal. Biochem., 1975, 69, 43-48. 
85. Winterbourn, C. C., Reaction of Duperoxide with Hemoglobin, CRC 
Handbook of Methods for Oxygen Radical Research, 1987, 137 -141. 
86. Reid Ill, T. J., Murthy, M. R. N., Sicignano A, Tanaka, N. Musick, W. D. L. 
and Rossmann, M. G., Proc. Natl. Acad. Sci. USA, Biochemistry, 1981, 78, 
4767-4771. 
87. Perutz M. F., J. Cryst. Growth., 1968, 2, 54-56. 
88. Ward, K. B., Wishner, B. C., Lattman, E. E. and Love, W. E., J. Mo/. Biol., 
1975, 98, 237-256. 
89.Arnone A, Rogers, P. H. and Briley, P. D., Biophysics and Physiology of 
Carbon Dioxide, Springer, Berlin, 1980, 67-74. 
90. Silver, M. M., Paul H. R. and Arnone A, J. Biol. Chem., 1992, 267, 17248-
17256. 
216 
91. Ockelford, P. A, Liang, A Y., Wells, R. M., Vissers, M., Brennan, S. 0., 
Williamson, D. and Carrell, R. W., Hemoglobin, 1980, 4, 295-306. 
92. Razynska, A, Rak, J., Fronticelli, C. and Bucci, E., J. Chem. Soc., Perkin 
Trans., 1991, 2, 1551-1540. 
93.March, J., Advanced Organic Chemistry, John Wiley & Sons, New York, 
1985, 348-351 . 
94. Mansouri, A and Winterhalter, K. H., Biochemistry, 1974, 13, 3311- 3314. 
95. Yang, T. and Olsen, K. W., Biochem. Biophys. Res. Commun., 1989, 163, 
733-738. 
96. Fermi, G., J. Mo/. Biol., 1975, 97, 237-256. 
97. Ladner, R. C., Haidner, E. J. and Perutz, M. F., J. Mo/. Biol., 1977, 114, 
385-414. 
98. Manning, L. R. and Manning, J.M., Biochemistry, 1988, 27, 6640-6644. 
99. Kavanaugh, M. P., Shih, D. T.-B. and Jones, R. T., Biochemistry, 1988, 27, 
1804-1808. 
100.Fantl, W. J., Manning, L. R., Ueno, H., Donato, A D. and Manning, J. M., 
Biochemistry, 1987, 26, 5755-5761. 
217 
Appendix I (a). 
To use this program, click the icon with a name of [HbA]&[Catalase] in 
Window 3.1 and use soft keys to perform the measurement. Press the soft key of 
F1 for input of user's name, date, sample name and selection of hemoglobin or 
catalase, F2 for reference scanning, F3 for sample scanning, F9 for printing 
results with data and a spectrum (see Appendix I (b)) and F10 for termination of the 
program. 
'$INCLUDE: '52 SETUP. BAS' 
'YAGUO ZHENG, 1995 
'TO CALCULATE CONCENTRATION OF HEMOGLOBIN, 
'PERCENTAGES OF METHEMOGLOBIN AND HEMICHROME. 
CLS 0 
KEY 1, " NAME" 
KEY 2, " BLANK" 
KEY 3, " SCAN" 
KEY 9' " PRINT" 
KEY 10, " EXIT" 
KEY ON 
PRINT "TURN ON 'HP 8452A'" 
KEY(l) ON 
ON KEY(l) GOSUB NAMING 
KEY(2) ON 
ON KEY(2) GOSUB REFFERE 
KEY(3) ON 
ON KEY(3) GOSUB SCANNIG 
KEY(9) ON 
ON KEY(9) GOSUB OUTCOPY 
KEY(lO) ON 
ON KEY(lO) GOSUB ENDPROG 
IDLE: GOTO IDLE 
REFFERE: 
CLS 0 
INPUT "ENTER THE AMOUNT (uL) OF BUFFER ADDED IN THE CELL"; A 
CLS 0 
PRINT "BLANKING" 
blank 
CLS 0 
RETURN 
SCANNIG: 
CLS 0 
INPUT "ENTER THE AMOUT (uL) OF SAMPLE ADDED IN THE CELL"; B 
CLS 0 
measure 
ini tplot RAW () 
plot RAW () , 15 
RETURN 
NAMING: 
CLS 0 
INPUT "ENTER USER NAME"; U$ 
INPUT "ENTER DATE"; D$ 
INPUT "ENTER SAMPLE NAME"; S$ 
CLS 0 
PRINT "Select:": PRINT 
COLOR 15, 0: PRINT " H"; 
COLOR 7, 0: PRINT "emoglobin" 
COLOR 15, 0: PRINT " C"; 
COLOR 7, 0: PRINT "atalase" 
INPUT Sel$ 
CLS 0 
RETURN 
OUTCOPY: 
LP RI NT 
LPRINT "*******************************************" 
LPRINT " 
LPRINT " 
LPRINT " 
USER: "; U$ 
DATE: "; D$ 
SAMPLE: "; S$ 
LPRINT "*******************************************" 
LP RI NT 
LPRINT "BUFFER ="; A; "uL": LPRINT 
LPRINT "SAMPLE ="; B; "uL" 
LP RI NT 
IF Sel$ = "H" OR Sel$ = "h" THEN 
HbA = (RAW(l77, 2) * (A+ B)) / (B * 13.8 * 4) 
D = RAW(256, 2) - .005 
IF D < 0 THEN D = 0 
Bl RAW(l86, 2) D 
B2 RAW(l94, 2) - D 
B3 RAW(221, 2) - D 
IF Bl < 0 THEN Bl 0 
IF B2 < 0 THEN B2 0 
IF B3 < 0 THEN B3 0 
OXYHBA = -89 * Bl + 119 *B2 -39 * B3 
MET = -55 * Bl + 28 *B2 + 307 * B3 
HEM! = 233 *Bl -133 * B2 -114 * B3 
IF MET < 0 THEN MET = 0 
IF HEM! < 0 THEN HEM! = 0 
METPT = 100 * MET / (OXYHBA + MET + HEM!) 
HEMIPT = 100 * HEM! / (OXYHBA + MET + HEM!) 
METHEMI = 100 * (MET + HEM!) / (OXYHBA + MET + HEM!) 
LPRINT RAW(l77, l); RAW(l77,2) 
LPRINT RAW(l86, l); RAW(l86, 2) 
LPRINT RAW(l94, l); RAW(l94, 2) 
LPRINT RAW(221, l); RAW(221, 2) 
LPRINT RAW(256, l); RAW(256, 2) 
LP RI NT 
LPRINT "CONCENTRATION OF HBA ="L HbA; "mM": LPRINT 
LPRINT "METHBA% ="; METPT; "%": LPRINT 
LPRINT "HEMICHROME% ="; HEMIPT; "%": LPRINT 
LPRINT "(METHBA+HEMICHRONE)% ="; METHEMI; "%": LPRINT 
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ELSEIF Sel$ 
MAX = 0 
"C" OR Sel$ 
FOR !% = 106 TO 121 
IF MAX < RAW(!%, 2) THEN 
MAX = RAW(!%, 2) 
MAXA = RAW(!%, 1) 
END IF 
"c" THEN 
CAT = MAX * (A + B) / (B * 420) 
LPRINT MAXA; MAX: LPRINT 
LPRINT "CONCENTRATION OF CATALASE ="; CAT; "mM": LPRINT 
END IF 
GETOUT: 
hardcopy 0, 344 
RETURN 
ENDPROG: 
CLS 0 
INPUT "EXIT (Y/N)"; A$ 
IF A$ = "Y" OR A$ = "y" THEN 
CLS 0 
END 
END IF 
RETURN 
HANDLER: 
LPRINT "DATA OVERFLOW" 
RESUME GETOUT 
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Appendix I (b ). Results of hemoglobin and catalase. 
USER: Yaguo Zheng 
DATE: 12/11/1995 
SAMPLE: New HbA 
****************************** 
542 .1019135 
560 5.897522E-02 
576 .1030884 
630 -l.l04736E-02 
700 -l.348877E-02 
BUFFER = 495 uL 
HbA = 5 uL 
CONCENTRATION OF HBA = .1846258 mM 
METHBA% = 0 % 
HEMICHROME% = .4322735 % 
(METHBA+HEMICHRONE)% = .4322735 % 
1 .. 812'4 
A 1.3235 B 
s 
0 
R o.a-
B 
A 
N 
c o.~ 
E 
- .. 14210 
- -
- .., ... lOO ... 
WAUELENGTH CNMJ 
1 llUll.!JI z SQllfl 3 fWll 4 S 6 ? 8 'J PlllMT 19 EXIT 
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USER: Yaguo Zheng 
DATE: l/25/1996 
SAMPLE: Catalase 
******************************************* 
BUFFER = 495 uL 
SAMPLE = 5 uL 
422 . 7640839 
CONCENTRATION OF CATALASE = .1819247 mM 
A 
B 
s 
0 
? 
B 
A 
N 
..,,.,1 
2.a101 
c 0.1•-
E \~ 
o.aooo 11----~------======::::::====-====-"""" 200 JOO 
-
500 100 IOO 
WAIJELENGiH CNM) 
1 MAflE 2 IUWfll 3 SCAll 4 S & 7 B 9 PRINT 111 EXIT 
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Appendix II. 
C PROGRAM TEST 
C YAGUO ZHENG 
c 1993 
CHARACTER*l AT(6), AN(4), RES(3), CH(l), K(6), L(4), S(80) 
INTEGER I, IN, FT 
N=O 
20 N=N+l 
IF (N.GE.204.AND.N.LE.4986) THEN 
READ(5, 10) AT,I,AN,RES,CH,IN,Xl,Yl,Zl,O,B,FT,K,L 
10 FORMAT(6Al,I5,2X,4Al,3Al,1X,Al,I4,4X,3F8.3,2F6.2,lX,I3,6Al,4Al) 
C TRANSFORM INTO UNIT CELL COORDINATES 
X2=(0.015462*Xl+0.002192*Yl+0.003698*Zl+0.26656)+0.5 
Y2=(-0.001902*Xl+0.011771*Yl+0.000974*Zl+0.16413) 
Z2=(-0.001061*Xl-0.001721*Yl+0.018728*Zl+0.75059) 
C ORTHOGONALIZE COOPERATES 
X3=63.150*X2-8.73l*Z2 
Y3=83.590*Y2 
Z3=53.087*Z2 
WRITE(6,10) AT,I,AN,RES,CH,IN,X3,Y3,Z3,0,B,FT,K,L 
ELSE 
READ(5,15,END=100) S 
15 FORMAT(BOAl) 
WRITE(6,15) S 
END IF 
GOTO 20 
100 STOP 
END 
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Appendix Ill. 
C PROGRAM MODEL 
C YAGUO ZHENG, 1993 
INTEGER I,IN,FT,M,N,J,K,U,V 
DIMENSION (54,4783),Y(54,4783),Z(54,4783),AN(4783),CH(4783) 
1I(4783),IN(4783),0(4783),B(4783),L(4783),RES(4783),AT1(4783), 
2AT2 (4783) 
M=O 
20 M=M+l 
READ (5,10,END=lOO) AT1(M),AT2(M),I(M),AN(M),RES(M),CH(M), 
3IN(M),Xl,Yl,Zl,O(M),B(M),S,L(M) 
10 FORMAT (2A3,I5,2X,A4,A3,1X,Al,I4,4X,3F8.3,2F6.2,6X,A4,I4) 
C TRANSFORM INTO UNIT CELL COORDINATES 
C MAKE #1 HEMOGLOBIN 
X(l,M)=0.015462*Xl+0.002192*Yl+0.003698*Zl+0.26656 
Y(l,M)=-0.001902*Xl+0.011771*Yl+0.000974*Zl+0.16413 
Z(l,M)=-0.001062*Xl+0.001721*Yl+0.018728*Zl+0.75059 
C MAKE #2 HEMOGLOBIN 
X(2,M)=X(l,M)+l.OOO 
Y(2,M)=Y(l,M) 
Z(2,M)=Z(l,M) 
C MAKE #3 HEMOGLOBIN 
X(3,M)=X(l,M) 
Y(3,M)=Y(l,M) 
Z(3,M)=Z(l,M)+l.OOO 
C MAKE #4 HEMOGLOBIN 
X(4,M)=X(l,M)+l.OO 
Y(4,M)=Y(l,M) 
Z(4,M)=Z(l,M)+l.OOO 
C MAKE #5 HEMOGLOBIN 
X(5,M)=l.000-X(l,M) 
Y(5,M)=Y(l,M)+0.500 
Z(5,M)=2.000-Z(l,M) 
C MAKE #6 HEMOGLOBIN 
X(6,M)=l.000-X(l,M) 
Y(6,M)=Y(l,M)-0.500 
Z(6,M)=2.000-Z(l,M) 
GOTO 20 
C ORTHOGONALIZE COORDINATES 
100 DO 300,J=l,6 
DO 300,K=l,4783 
Z(J,K)=53.800*Z(J,K)-10.249*X(J,K) 
X(J,K)=62.313*X(J,K) 
Y(J,K)=83.590*Y(J,K) 
C PRINT #1-6 HEMOGLOBIN 
WRITE (6,10) ATl(K),AT2(K),I(K),AN(K),RES(K),CH(K),IN(K), 
4X(J,K),Y(J,K),Z(J,K),O(K),B(K),S,L(K) 
300 CONTINUE 
STOP 
END 
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Appendix IV. 
DECLARE SUB PAUSE (Q$) 
'$INCLUDE: '52SETUP. BAS' 
REM 
REM 
REM 
REM 
REM 
REM 
*********************************************** 
*** 
*** 
*** 
*** 
YAGUO ZHENG 
1995 
*** 
*** 
*** 
*** 
*********************************************** 
REM MAIN MANR 
'TO PROVIDE A MANU TO SELECT DESIRED WORK 
DIM C(l TO 1) AS INTEGER, BS(l TO 7) AS INTEGER, F(l TO 1) AS INTEGER 
DIM A(l TO 103), B(l TO 103, 1 TO 2), D(l TO 103), T(l TO 103) 
DO 
CLS 
SCREEN 1 
CIRCLE (40, 42), 10, 2: PAINT (40, 42), 2 
CIRCLE (60, 42), 10, 2: PAINT (60, 42), 2 
CIRCLE (40, 58), 10, 2: PAINT (40, 58), 2 
CIRCLE (60, 58), 10, 2: PAINT (60, 58), 2 
LINE (38, 40)-(62, 60), 1, B 
LINE (39, 41)-(61, 59), 1, B 
LINE (41, 43)-(59, 57), 1, B 
LINE (42, 44)- (58, 56), 1, B 
CIRCLE (50, SO), 1, 3 
CIRCLE (260, 42), 10, 2: PAINT 
CIRCLE (280, 42), 10, 2: PAINT 
CIRCLE (260, 58), 10, 2: PAINT 
CIRCLE (280, 58), 10, 2: PAINT 
LINE (258, 40)- (282, 60), 1, B 
LINE (259, 41)-(281, 59), 1, B 
LINE (261, 43)-(279, 57), 1, B 
LINE (262, 44)-(278, 56), 1, B 
CIRCLE (270, 50), 1, 3 
LINE (80, 20)- (240, 80), 1, B 
LINE (81, 21)-(239, 79), 1, B 
LINE (83, 23)-(237, 77), 1, B 
LINE (118, 66)-(193, 66), 1 
(260, 
(280, 
(260, 
(280, 
LOCATE 5, 15: PRINT "AUTOXIDATION" 
LOCATE 6, 14: PRINT "& DENATURATION" 
LOCATE 8, 16: PRINT "Olsen Lab" 
LINE (20, 98)-(150, 118), 2, B 
LINE (170, 98)-(300, 118), 2, B 
LINE (20, 130)-(150, 150), 2, B 
LINE (170, 130)-(300, 150), 2, B 
LINE (20, 161)-(150, 181), 2, B 
LINE (170, 161)-(300, 181), 2, B 
LOCATE 14, 4: PRINT "(P)reparation" 
LOCATE 14, 23: PRINT "(B)eststep" 
LOCATE 18, 4: PRINT "(A)utoxidation" 
42), 2 
42), 2 
58), 2 
58), 2 
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LOCATE 18, 23; PRINT "(D)enaturation" 
LOCATE 22, 4: PRINT "(R)esults" 
LOCATE 22, 23: PRINT "(E)xit" 
DO 
Q$ = UCASE$(INPUT$(1)) 
LOOP WHILE INSTR ( "RBDPAE", Q$) 0 
CLS 
SELECT CASE Q$ 
CASE IS = "P" 
GOSUB CONCENTRATN 
CASE IS = "B" 
GOSUB BESTSTEP 
CASE IS = "D" 
GOSUB DENATURATION 
CASE IS = "R" 
GOSUB PRINTG 
CASE IS = "A" 
GOSUB AUTOXIDATION 
CASE ELSE 
END SELECT 
LOOP UNTIL Q$ = "E" 
END 
BESTSTEP: 
REM BESTSTEP 
'TO OBTAIN THE OPTIMAL POSITION FOR EACH CELL 
SCREEN 9 
CLS 
PRINT "BESTSTEP SECTION": PRINT 
PRINT "INSERT A FORMATED HD DISK IN DRIVE B." 
PAUSSE B$ 
IF B$ = "Q" THEN RETURN 
NUMWAVES = 1 
WAVELIST(l) = 416 
INTMODE = 2 
WAVEMODE = 1 
GAIN = 0 
OPEN "O", 1, "B:\BESTSTEP" 
CLS 
FOR I% = 1 TO 7 
XLABEL$ = "STEP NUMBER" 
YLABEL$ = "COUNT" 
PRINT "MEASURING CELL #"; I% 
MINSTEP% = (I% - 1) * 1075 
MAXSTEP% = MINSTEP% + 400 
MAXINTENT! = 0 
DRAWAXES CSNG(MINSTEP%), CSNG(MAXSTEP%), 500, 3000 
FOR J% = MINSTEP% TO MAXSTEP% STEP 4 
TRANSPORTSTEP J% 
measure 
COLOR 15, 0 
IF J% = MINSTEP% THEN 
PRESEP (J%, RAW(l, 2)) 
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ELSE 
LINE - (J%, RAW(l, 2)) 
END IF 
IF RAW(l, 2) > MAXINTENT THEN 
MAXINTENT! = RAW(l, 2) 
MAXSTEP% = J% 
END IF 
NEXT J% 
PRINT #1, I%, MAXSTEP% 
CMD$ = "CEL" + STR$(I%) + STR$(MAXSTEP) 
SEND8452 CMD$ 
CLS 0 
NEXT I% 
CLOSE #1 
PRINT 
PRINT "THE BESTSTEP DATA ARE SAVED IN THE FILE NAMED 'BESTSTEP' ." 
PRINT 
OPEN "I", 1, "B:\BESTSTEP" 
FOR I% = 1 TO 7 
INPUT #1, I%, A 
PRINT I%, A 
NEXT I% 
CLOSE #1 
PRINT 
PRINT "THE BESTSTEP IS OVER." 
PRINT "PRESS ANY KEY TO GO BACK THE MAIN MENU." 
WHILE INKEY$ = "": WEND 
RETURN 
CONCENTRATN: 
REM $DYNAMIC 
SCREEN 9 
REM CONCENTRATION 
'TO ADJUST HEMOGLOBIN CONCENTRATION OF SAMPLES 
CLS 
PRINT "PREPARATION OF CONCENTRATION OF Hb SAMPLES." 
PRINT 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
DO 
PRINT "SELECT:": PRINT 
PRINT "DENATURATION-PRISS 1 THEN <ENTER>." 
INPUT "AUTOXIDATION-PRESS 2 THEN <ENTER>." 
CLS 
LOOP WHILE A < 1 OR A > 2 
PRINT "ADD 500 ul OF THE BUFFER TO EACH OF 7 CELLS." 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
PRINT "A. INSERT ALL THE 7 CELLS." 
PRINT "B. CLOSE THE DOOR." 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
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FOR I% = 2 TO 7 
HOME 
CELL I% 
blank 
PRINT "ADD STARTING AMOUNT (ul) OF Hb SAMPLE"; I% - 1 
PRINT "TO CELL"; I%; "." 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
DO 
NUMWAVES = 1 
INTMODE = 0 
WAVEMODE = 1 
WAVELIST(l) 416 
measure 
IF RAW(l, 2) < A THEN 
PRINT "THE ABSORBANCE AT"; RAW(l, l); "IS"; RAW(l, 2); 
PRINT "ADD MORE Hb SAMPLE IN CELL #"; I%; "." 
ELSEIF RAW(l, 2) >A+ .1 THEN 
PRINT "THE ABSORBANCE AT"; RAW(l, l); "IS"; RAW(l, 2); 
PRINT "THERE IS TOO MUCH SAMPLE IN CELL"; I%; " " 
PRINT "ADJUST Hb CONCENTRATION AGAIN." 
ELSE 
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\\ ,, 
" ,, 
PRINT "THE ABSORBANCE AT"; RAW ( 1, 1) ; "IS"; RAW ( 1, 2) ; " " 
PRINT "THE CONCENTRATION IS FINE, GO ON." 
END IF 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
LOOP WHILE RAW(l, 2)< A OR RAW(l, 2)= A+ .1 OR RAW(l, 2) >A+ .1 
NEXT I% 
IF A = 1 THEN 
A$ = "DENATURATION." 
PRINT "ADD 5 ul OF 9.7 x 100 uM K3Fe(CN)6 SOLUTION TO EACH CELL." 
ELSE 
A$ = "AUTOXIDATION." 
END IF 
PRINT PRINT "TIGHTEN DOWN THE CELL CHANGER." 
PRINT PRINT "THE SAMPLES ARE READY FOR "; A$ 
PRINT PRINT "PRESS ANY KEY TO GO BACK THE MAIN MANU." 
WHILE _INKEY$ = '"': WEND 
CLS 
RETURN 
DENATURATION: 
REM DENATRUATION 
SCREEN 9 
PRINT : PRINT "DENATURATION SECTION" 
PAUSE B$ 
IF B$ "Q" THEN RETURN 
INTMODE = 0 
WAVEMODE = 1 
NUMWAVES = 7 
WAVELIST(l) = 280 
WAVELIST(2) 406 
WAVELIST(3) 410 
WAVELIST(4) 418 
WAVELIST(5) 542 
WAVELIST(6) 576 
WAVELIST(7) 630 
C(l) = 0 
TIMECOUNT = 0 
PRINT "SEVEN WAVELENTHES ARE USED IN THE TEST:": PRINT 
FOR I% = 1 TO 7 
PRINT "LAMDA"; I%; "="; WAVELIST(I%) 
NEXT I% 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
ON ERROR GOTO BIND 
OPEN "I", 1, "B: \BESTSTEP" 
FOR I% = 1 TO 7 
INPUT #1, I%, BS(I%) 
NEXT I% 
CLOSE #1 
CLS 
FOR I% = 2 TO 7 
FORWARD: 
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PRINT "ENTER FILE NAME FOR SAMPLE #"; I% - 1; "IN CELL #"; I% 
INPUT N$ 
ON ERROR GOTO GETFILE 
OPEN "O", I%, "B:" + N$ 
NEXT I% 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
CLS 
PRINT "SET UP TEMPERATURN CONTROL SYSTEN.": PRINT 
PRINT 
PRINT 
PRINT 
PRINT 
PIRNT 
PAUSE 
IF B$ 
PRINT 
PRINT 
PRINT 
PRINT 
PRINT 
PRINT 
PRINT 
PRINT 
PRINT 
"A, BATH DIAL= 80 ON 'RTE-9' ." 
B$ 
PRINT "B. TEMPERATURE DIAL = 0 ON 'ETP-3' ." 
PRINT "C. PROGRAM= HOLD ON 'ETP-3' ." 
PRINT "D. BATH SWITCH = -20 TO +35 DEG C ON 'RTE-9' ." 
PRINT "E, ACCESSORY INPUT = ENABLE ON 'DCR-4' ." 
"Q" THEN RETURN 
PRINT "F. PRESS & HOLD SETPOINT/SENSOR TEMP BOTTON AND" 
PRINT " ADJUST SETPOINT = 29 DEG C ON 'DCR-4' ." 
PRINT "G. PROGRAM END = HOLD, HEAT/COOL = HEAT & FWD/REV" 
PRINT " = REV ON 'ETP-3." 
PRINT "H. PRESS START/RESET BUTTON ON 'ETP-3' (NOTE: PROGRAM" 
PRINT " END LIGHT IS OFF & METER IS AT 1) ." 
PRINT "I. TIME = 210 min ON 'ETP-3' ." 
PRINT "J. PRESS & HOLD BUTTON ON 'SET PROGRAM' ADAPTER CABLE" 
PRINT " BOX AND ADJUST TEMPERATURE DIAL = 50.0 ON 'SET-3'" 
PRINT PRINT " THEN RELEASE BOTTON." 
PAUSE B$ 
IF B$ 
PRINT 
PIRNT 
"Q" THEN RETURN 
PRINT "K. FWD/REV= FWD ON 'ETP-3' ." 
PRINT "L. PRESS START/RESET BUTTON (NOTE: PROGRAM END LIGHE" 
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PRINT PRINT " IS OFF AND METER IS AT 0) ." 
PRINT PRINT "M. ON 'SET PROGRAM' ADAPTER CABLE BOX, ENABLE/DISABLE" 
PRINT PRINT " = ENABLE." 
PRINT PRINT "N. BATH SWITCH = +35 TO +100 DEG C ON 'RTE-9' ." 
PRINT PRINT "WHEN READY FOR DENATURATION, PROGRAM= RUN ON 'ETP-3'" 
PRINT PRINT " AND CONTINUE." 
PAUSE B$ 
IF B$ = "Q' THEN RETURN 
CLS 
INPUT "INPUT THE CURRENT TEMPERATURE"; T 
CLS 
PRINT "THE DENATURATION PROGRAM IS WORKING." 
PRINT : PRINT T: PRINT 
F(l) = CINT(T * 10) 
HOME 
FOR I% = 1 TO 103 
TRANSPORTSTEP BS(l) 
blank 
FOR J% = 2 TO 7 
START! = TIMER 
TIMER ON 
ON TIMER(15) GOSUB DENAT 
STAY: GOTO STAY 
THERE: 
FINISH! = TIMER 
TIMECOUNT = TIMECOUNT + (FINISH! - START!) / 60 
PRINT "TIME"; C(l); "="; FINISH! - START!; "sec" 
PRINT "TOTAL TIME: "; TIMECOUNT; "min": PRINT 
NEXT J% 
NEXT I% 
TIMER OFF 
FOR I% = 2 TO 7 
CLOSE #I% 
NEXT I% 
PRINT "DENATURATION IS OVER." 
PRINT : PRINT "TURN OFF THE TEMPERATURE CONTROL SYSTEM." 
PRINT "PRESS ANY KEY BACK THE MAIN MANU." 
WHILE INKEY$ = "": WEND 
MERROR: 
RETURN 
DENAT: 
BEEP 
INPUT "DELTA TEMPERATURE"; A 
F(l) = F(l) +A 
T = F(l) * .1 
PRINT T 
ON ERROR GOTO TERROR 
PRINT #J%, T 
TRANSPORTSTEP BS(J%) 
measure 
FOR K% = 1 TO 7 
PRINT #J%, RAW(K%, 2) 
NEXT K% 
C(l) = C(l) + 1 
RETURN THERE 
GETFILE: 
PRINT : PRINT "DISK ERROR OR DRIVE B IS EMPTY!": PRINT 
RESUME FORWARD 
BIND: 
PRINT "FILE NAMED BESTSTEP CAN NOT BE FOUND." 
PRINT "PLEASE MAKE SURE IT IS IN YOUE DISK." 
PRINT "PRESS ANY KEY TO CONTINUE.: 
WHILE INKEY$ = "": WEND 
RESUME 
TERROR: 
PRINT : PRINT "ERROR! PLEASE WAIT.": PRINT 
RESUME MERROR 
AUTOXIDATION: 
REM AUTOXIDATION 
SCREEN 9 
CLS 
PRINT "AUTOXIDATION SECTION": PRINT 
PAUSE B$ 
IF B$ "Q" THEN RETURN 
INTMODE = 0 
WAVEMODE = 1 
NUMWAVES = 4 
WAVELIST(l) 560 
WAVELIST(2) 576 
WAVELIST(3) 630 
WAVELIST(4) 700 
CLS 
PRINT "SET TEMPERATURE ON 'DCR-4' AT 39 DEG C." 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
ON ERROR GOTO FIND 
OPEN "I", 1, "B:\BESTSTEP" 
FOR I% = 1 TO 7 
INPUT #1, I%, BS(I%) 
NEXT I% 
CLOSE #1 
CLS 
FOR I% = 2 TO 7 
STRAIGHT: 
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PRINT "ENTER FILE NAME FOR SAMPLE #"; I% - 1; "IN CELL #"; I% 
INPUT N$ 
ON ERROR GOTO SETFILE 
OPEN "O", I%, "B:" + N$ 
NEXT I% 
PAUSE B$ 
IF B$ = 'Q" THEN RETURN 
CLS 
PRINT "ADJUST AND WAIT UNTIL THE TEMPERATURE IS" 
PRINT "STABLE AT 37 DEG C NO OMEGA DIGICATOR." 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
CLS 
PRINT "THE AUTOXIDATION PROGRAM IS WORKING.": PRINT 
HOME 
FOR J% = 1 TO 7 
IF J% = 1 THEN 
TRANSPORTSTEP BS(l) 
blank 
ELSE 
TRANSPORTSTEP BS(J%) 
measure 
FOR K% = 1 TO 4 
PRINT #(J%), RAW(K%, 2) 
NEXT K% 
END IF 
NEXT J% 
FOR I% = 1 TO 34 
START! = TIMER 
HOME 
TIMER ON 
ON TIMER(1775.2) COSUB AUTOX 
IDLE: GOTO IDLE 
HERE: 
FINISH! = TIMER 
PRINT "TIME"; I%; 
NEXT I% 
TIMER OFF 
FOR I% = 2 TO 7 
CLOSE #I% 
NEXT I% 
"-". 
- I (FINISH! - START!) I 60; "min", 
PRINT PRINT : PRINT "AUTOXIDATION IS OVER." 
PRINT "PRESS ANY KEY BACK THE MAIN MANU." 
WHILE INKEY$ = "": WEND 
RETURN 
AUTOX: 
FOR J% = 1 TO 7 
IF J% = 1 THEN 
TRANSPORTSTEP BS(l) 
blank 
ELSE 
TRANSPORTSTEP BS(J%) 
measure 
FOR K% = 1 TO 4 
PRINT #(J%), RAW(K%, 2) 
NEXT K% 
EMD IF 
NEXT J% 
RETURN HERE 
SETFILE: 
PRINT : PRINT "DISK ERROR OR DRIVE B IS EMPTY!": PRINT 
RESUMR STRAIGHT 
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FIND: 
PRINT "FILE NAMED BESTSTEP CAN NOT BE FOUND." 
PRINT "PLEASE MAKE SURE IT IS IN YOUR DISK." 
PAUSE 8$ 
IF 8$ "Q' THEN RETURN 
RESUME 
PRINTG: 
REM PRINTING 
'THIS PART OF PROGRAM IS TO PRINT OUT 
'AUTOXIDEATION AND/OR DENATURATION RESULTS 
SCREEN 9 
CLS 
PRINT "DATA ANALYSIS" 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
C(l) = 0 
DO 
PRINT "PRINT:": PRINT 
PRINT " DENATURATION-PRESS 1 THEN <ENTER>" 
INPUT " AUTOXIDATION-PRESS 2 THEN <ENTER>"; A 
CLS 
LOOP WHILE A < 1 OR A > 2 
IF A = 1 THEN 
GOSUB PDENAT 
ELSE 
GOSUB PAUTOX 
END IF 
RETURN 
PDENAT: 
CLS 0 
PRINT "DATA ANALYSIS OF DENATRATION": PRINT 
PAUSE B$ 
IF B$ = "Q" THEN RETURN 
DO 
INPUT "ENTER FILE NAME"; N$ 
ON ERROR GOTO FILENAME 
OPEN "I", 1, "B:" + N$ 
INPUT "ENTER WAVELENTH #"; W 
INPUT "ENTER A TITLE FOR THE PLOT."; T$ 
CLS 0 
FOR I% = 1 TO 103 
ON ERROR GOTO DATAHDL 
INPUT #1, T (I%) 
FOR J% = 1 TO 7 
IF J% = W THEN 
INPUT #1, A(I%) 
ELSE 
INPUT #1, C 
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END IF 
NEXT J% 
NEXT I% 
m = 102 
FLOPPING: 
CLOSE #1 
FOR I% = 1 TO m 
TEMPERl = A(I% + 1) - A(I%) 
TEMPER2 = T(I% + 1) - T(I%) 
ON ERROR GOTO DATACUT 
D(I%) = TEMPERl / TEMPER2 
NEXT I% 
N = 102 
SKIPPING: 
FOR I% = 11 TO N - 10 
TEMPl 329 * D(I%) + 324 * (D(I% + 1) + D(I% - 1)) 
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TEMP2 309*(D(I%+2) + D(I%-2))+ 284 * (D(I% + 3) + D(I% 3)) 
TEMP3 249*(D(I%+4) + D(I%-4))+ 204 * (D(I% + S) * D(I% S)) 
TEMP4 149*(D(I%+6) + D(I%-6)) + 84 * (D(I% + 7) + D(I% 7)) 
TEMPS 9 * (D(I%+8) + D(I%-8)) - 76 * (D(I% + 9) + D(I% - 9)) 
TEMP6 -(171 * (D(I% + 10) + D(I% - 10))) 
B(I% - 10, 2) (TEMPl +TEMP2 +TEMP3 +TEMP4 +TEMPS +TEMP6)/30S9 
B(I% - 10, 1) (T(I% + 1) + T(I%)) / 2 
NEXT I% 
TITLE$ = T$ 
YLABEL$ = "dA/dT" 
XLABEL$ ="TEMPERATURE (DEG C)" 
YAUTOSCALE B(), 80, YMIN!, YMAX! 
DRAWAXES 28!, 70!, YMIN!, YMAX! 
COLOR lS, 0 
FOR I% = 1 TO N - 21 
IF I% = 1 THEN 
PRESET (B(I%, 1) ' B(I%, 2)) 
ELSE 
LINE - (B(I%, 1) ' B(I%, 2)) 
END IF 
NEXT I% 
INPUT "SAVE THE DATA (Y/N)"; A$ 
CLS 0 
COLOR 7, 0 
IF A$ = "Y" OR A$ = "y" THEN 
W$ = LTRIM$ (STR$ (W)) 
OPEN "O", 1, "B:\" + N$ + "W" + W$ 
PRINT "THE DATA ARE SAVED IN FILE "; N$ + "W" + W$ 
FOR I% = 1 TO N - 21 
PRINT B(I%, 1); B(I%, 2), 
PRINT #1, B(I%, 1) 
NEXT I% 
FOR I% = 1 TO N - 21 
PRINT #1, B(I%, 2) 
NEXT I% 
CLOSE #1 
END IF 
PRINT : INPUT "DO MORE FILES (Y/N)"; A$ 
CLS 0 
LOOP WHILE A$ = "Y" OR A$ = "y" 
RETURN 
PAUTOX: 
CLS 0 
PRINT "DATA ANALYSIS OF AUTOXIDATION": PRINT 
PAUSE 8$ 
IF 8$ = "Q" THEN RETURN 
DO 
INPUT "ENTER FILE NAME"; N$ 
ON ERROR GOTO FILENAME 
OPEN "I", 1, "B:" + N$ 
INPUT "ENTER A TITLE FOR THE PLOT"; T$ 
CLS 0 
TITLE$ = T$ 
YLABEL$ = "LN[OXYHbA]" 
XLABEL$ ="TIME (HOUR)" 
DRAWAXES 0, 18, 0, 3 
x = 0 
y = 0 
XSQU 0 
YSQU 0 
XY = 0 
FOR I% = 1 TO 35 
FOR J% = 1 TO 4 
INPUT #1, A(J%) 
NEXT J% 
HBA = 119 * A(2) - 39 * A(3) - 89 * A(l) + 9 * A(4) - .045 
B(I%, 2) = LOG(HBA) 
B (I%, 1) = (I% - 1) I 2 
COLOR 15, 0 
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LINE (B(I%,1)-.1, B(I%,2)-.02)-(B(I%,1)+.1, B(I%,2)+.02),, BF 
x = x + B(I%, 1) 
XSQU = XSQU + B(I%, 1) * B(I%, 1) 
Y = Y + B(I%, 2) 
YSQU = YSQU + B(I%, 2) * B(I%, 2) 
XY = XY + B(I%, 1) * B(I%, 2) 
NEXT I% 
CLOSE #1 
LXX XSQU - (x *x) / 35 
LYY YSQU - (Y * Y) / 35 
LXY XY - (x *Y) I 35 
slope! = LXY / LXX 
intercept! = (Y - slope! * x) I 35 
coeff! = ABS(LXY I (LXX * LYY) A .5) 
FOR I% = 1 TO 35 
B(I%, 2) = intercept! + slope! * B(I%, 1) 
IF I% = 1 THEN 
PRESET (B(I%, 1), B(I%, 2)), red 
ELSE 
LINE - (B(I%, 1), B(I%, 2)), red 
END IF 
NEXT I% 
'HARDCOPY 0, 344 
PRINT "PRESS ANY KEY TO CONTINUE." 
WHILE INKEY$ = '"': WEND 
CLS 0 
OPEN "O", 1, "B:\" + N$ +"DAT" 
PRINT "THE DATA ARE SAVED IN FILE "; N$ + "DAT.": PRINT 
PRINT #1, "SLOPE ": PRINT #1, slope! 
PRINT #1, "INTERCEPT ": PRINT #1, intercept! 
PRINT #1, "R ": PRINT #1, coeff! 
PRINT "SLOPE"; slope!, "INTERCEPT"; intercept!, "R "; coeff! 
PRINT #1, : PRINT 
FOR I% = 1 TO 35 
PRINT #1, B(I%, 2) 
PRINT B(I%, l); B(I%, 2), 
NEXT I% 
CLOSE #1 
PRINT 
INPUT "DO MORE FILES (Y/N)"; A$ 
CLS 0 
LOOP WHILE A$ = "Y" OR A$ = "y" 
RETURN 
FILENAME: 
PRINT "FILE NAMED "; N$; " CAN NOT BE FOUND." 
INPUT "ENTER FILE NAME"; N$ 
CLS 0 
RESUME 
DATACUT: 
N = I% - 1 
RESUME SKIPPING 
DATAHDL; 
m = I% - 2 
RESUME FLOPPING 
DEFINT A-Z 
REM $DYNAMIC 
SUB PAUSE (Q$) 
PRINT 
PRINT "SELECT:": PRINT 
COLOR 15, 0: PRINT " C"; 
COLOR 7, 0: PRINT "ontinue" 
COLOR 15, 0: PRINT " Q"; 
COLOR 7, 0: PRINT "uit (BACK TO THE MAIN MANU)" 
DO 
Q$ = UCASE$(INPUT$(1)) 
LOOP WHILE INSTR ( "CQ", Q$) 0 
CLS 
END SUB 
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Appendix V. 
The following describes how to run the denaturation and autoxidation 
program. When the icon with a name of autox&denat in Window 3.1 was clicked, 
a graphic menu was displayed on the screen. The experiment can follow the 
procedure: Preparation --> Beststep --> Autoxidation (or Denaturation) --> 
Results --> Exit. 
Preparation. 
Press "P" or "p" to prepare samples. The screen displays: 
PREPARATION OF CONCENTRATION OF SAMPLES 
Select: 
Continue 
Quit (go back the main menu) 
Press "C" or "c", 
(Screen): Select: 
Press "1", 
DENATURATION-PRESS 1 THEN <ENTER>. 
AUTOXIDATION-PRESS 2 THEN <ENTER>.? 
(Screen): ADD 500 ul OF THE BUFFER TO EACH OF 7 CELLS 
Press "C" or "c', 
(Screen): A INSERT ALL THE 7 CELLS. 
B. CLOSE THE COVER. 
Press "C" or "c", 
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(Screen): ADD STARTING AMOUNT (ul) OF Hb SAMPLE 1 TO CELL 2. 
Press "C" or "c", if 
(Screen): THE ABSORBANCE AT 416 IS x.xxxxxx. 
ADD MORE SAMPLE IN CELL 2. 
please add more sample in the cell and press "C" or "c". If 
(Screen): THE ABSORBANCE AT 416 IS x.xxxxxx. 
THERE IS TOO MUCH SAMPLE IN CELL 2. 
ADJUST Hb CONCENTRATION AGAIN. 
please add one or few drops of the buffer in the cell and press "C" or "c'. If 
(Screen): THE ABSORBANCE AT 416 IS x.xxxxxx. 
THE CONCENTRATION IS FINE, GO ON .. 
press "C" or "c'. 
(Screen): ADD 5 ul OF 9. 7 x 100 uM K3Fe(CN)6 SOLUTION TO EACH CELL. 
TIGHTEN DOWN THE CELL CHANGER. 
THE SAMPLES ARE READY FOR DENATURATION. 
PRESS ANY KEY TO GO BACK THE MAIN MENU. 
If press 2 for autoxidation, the same procedures will be followed without addition of 
~Fe(CN)s. 
Press any key to return to the main menu. 
Beststep. 
Press "B" or "b" and the screen displays: 
BESTSTEP SECTION 
INSERT A FORMATIED HD DISK IN DRIVE B. 
After inserting a formatted high density disk in the B drive, press "C" or "c". 
(Screen): Beststep spectra. 
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(Screen): THE BESTSTEP DATA ARE SAVED IN THE FILE NAMED 'BESTSTEP'. 
Beststep data. 
THE BESTSTEP IS OVER. 
PRESS ANY KEY TO GO BACK THE MAIN MENU. 
Press any key to return to the main menu. 
Autoxidation. 
Press "A" or "a", 
(Screen): AUTOXIDATION SECTION 
Press "C" or "c", 
(Screen): SET TEMPERATURE ON 'DCR-4' AT 39 DEG C. 
Press "C" or "c". If it is a wrong disk or the B drive is empty, 
(Screen): FILE NAMED BESTSTEP CAN NOT BE FOUND. 
PLEASE MAKE SURE IT IS IN YOUR DISK. 
Press "C" or "c" after checking the disk. 
(Screen): ENTER FILE NAME FOR SAMPLE # 1 IN CELL# 2 
? 
After repeating inputting six file names, press "C" or "c". 
(Screen): ADJUST AND WAIT UNTIL THE TEMPERATURE IS 
STABLE AT 37 DEG CON OMEGA DIGICATOR. 
Press "C" or "c", 
(Screen): THE AUTOXIDATION PROGRAM IS WORKING. 
TIME 1 = 30 MIN TIME 2 = 30 min ...... TIME 15 = 30 min 
AUTOXIDATION IS OVER. 
PRESS ANY KEY TO GO BACK THE MAIN MENU. 
Press any key to return to the main menu. 
Denaturation. 
Press "D" or "d", 
(screen): DENATURATION SECTION 
Press "C" or "c", 
(Screen): SEVEN WAVELENGTHS ARE USED IN THE TEST: 
Seven wavelengths. 
Press "C" or "c", 
(Screen): ENTER FILE NAME FOR SAMPLE # 1 IN CELL# 2 
? 
Type in six file names and press "C" and "c", 
(Screen): Instruction of temperature control system. 
Press "C" or "c', 
(Screen): INPUT THE CURRENT TEMPERATURE? 
Type the temperature (e.g.: 28.0) showed on the OMEGA DIGICATOR. 
(Screen): THE DENATURATION PROGRAM IS WORKING. 
28.0 
DEL TA TEMPERATURE? 
Input the difference of temperature (e.g.: 1 ), 
(Screen): 28.1 
TIME 1 = 19.9092 sec 
TOTAL TIME: 0.3318 min 
Continue inputting temperatures until 618 points are added. 
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(Screen): DENATURATION IS OVER. 
TURN OFF THE TEMPERATURE CONTROL SYSTEM. 
PRESS ANY KEY TO GO BACK THE MAIN MENU. 
Press any key to return to the main menu. 
Results. 
Press "R" or "r", 
(Screen): DATA ANALYSIS 
Press "C" or "c", 
(Screen): RESULT OF 
DE NATURA TION-PRESS 1 THEN <ENTER> 
AUTOXIDATION-PRESS 2 THEN <ENTER> ? 
Type 1 for denaturation results. 
(Screen): DATA ANALYSIS OF DENATURATION 
Press "C" or "c". 
(Screen): ENTER FILE NAME ? 
Type a file name (e.g.: dena1) saved in the disk. 
(Screen): ENTER WAVELENGTH#? 
Type a number (e.g.: 2). 
(screen): SAVE THE DATA (Y/N)? 
A denaturation diagram. 
If press "Y' or "y'', 
(Screen): THE DATAARE SAVED IN FILE DENA1W2 
Denaturation data. 
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DO MORE FILE (YIN) ? 
Press "Y'' or "y'' to repeat data analysis or press another key to go back the main 
menu. 
Type 2 for autoxidation results. 
(Screen): DATA ANALYSIS OF AUTOXIDATION 
Press "C" or "c". 
(Screen): ENTER FILE NAME ? 
Type a file name (e.g.: auto1) saved in the disk. 
Continue. 
(Screen): PRESS ANY KEY TO CONTINUE. 
An autoxidation diagram. 
(Screen): THE DATA ARE SAVED IN FILE AUT01 DAT 
Autoxidation data. 
DO MORE FILES (Y/N) ? 
Press "Y'' or "y'' to continue or press another key to return to the main menu. 
Exit. Press "E" or "e" to terminate the program. 
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